Mmp9 (matrix metallopeptidase 9) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Mmp9 (matrix metallopeptidase 9) Rattus norvegicus
Analyze
Symbol: Mmp9
Name: matrix metallopeptidase 9
RGD ID: 621320
Description: Enables fibronectin binding activity and metallopeptidase activity. Involved in several processes, including cellular response to cell-matrix adhesion; cellular response to cytokine stimulus; and cellular response to iron(III) ion. Located in extracellular space. Part of protein-containing complex. Is active in several cellular components, including Schaffer collateral - CA1 synapse; extracellular matrix of synaptic cleft; and postsynaptic density, intracellular component. Used to study artery disease (multiple); brain ischemia (multiple); congestive heart failure; glomerulosclerosis; and lung disease (multiple). Biomarker of several diseases, including artery disease (multiple); brain disease (multiple); chronic obstructive pulmonary disease (multiple); glucose metabolism disease (multiple); and kidney disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including Down syndrome; anodontia; artery disease (multiple); autoimmune disease (multiple); and chronic obstructive pulmonary disease (multiple). Orthologous to human MMP9 (matrix metallopeptidase 9); PARTICIPATES IN fibroblast growth factor signaling pathway; syndecan signaling pathway; urinary bladder cancer pathway; INTERACTS WITH (+)-Tetrandrine; (R)-carnitine; (R)-noradrenaline.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: 92 kDa gelatinase; 92 kDa type IV collagenase; 92-kDa type IV collagenase; gelatinase B; GELB; matrix metalloproteinase 9 (gelatinase B 92-kDa type IV collagenase); matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase); matrix metalloproteinase-9; MMP-9
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Mmp9em6Mcwi ; Mmp9em4Mcwi
Genetic Models: SS-Mmp9em4Mcwi ; SS-Mmp9em6Mcwi
Candidate Gene For: Eau4
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr83174,103,474 - 174,111,434 (+)NCBIGRCr8
mRatBN7.23153,684,158 - 153,692,118 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl3153,683,858 - 153,692,120 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx3157,492,813 - 157,500,796 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.03165,991,783 - 165,999,766 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.03163,735,564 - 163,743,543 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.03161,413,410 - 161,421,473 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl3161,413,298 - 161,421,520 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.03167,578,904 - 167,605,890 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.43155,985,473 - 155,993,433 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.13155,891,508 - 155,899,467 (+)NCBI
Celera3152,289,466 - 152,297,426 (+)NCBICelera
Cytogenetic Map3q42NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (IDA,ISO)
Acute Coronary Syndrome  (ISO)
Acute Lung Injury  (IEP)
Acute Otitis Media  (ISO)
adenosine deaminase deficiency  (ISO)
adrenoleukodystrophy  (ISO)
adult respiratory distress syndrome  (ISO)
Albuminuria  (ISO)
alcohol use disorder  (IEP)
Alcoholic Liver Diseases  (IEP)
allergic contact dermatitis  (IEP,ISO)
Alveolar Bone Loss  (IEP)
Alzheimer's disease  (ISO)
amyotrophic lateral sclerosis  (ISO)
angle-closure glaucoma  (ISO)
Animal Disease Models  (ISO)
Animal Mammary Neoplasms  (ISO)
anodontia  (ISO)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis  (ISO)
aortic aneurysm  (ISO)
aortic disease  (ISO)
aortic dissection  (ISO)
Aortic Rupture  (ISO)
Arterial Injury  (IDA)
arteriosclerosis  (IDA,ISO)
Arteriovenous Fistula  (IEP,ISO)
arteriovenous malformation  (ISO)
asthma  (IEP,ISO)
atopic dermatitis  (ISO)
atrial fibrillation  (ISO)
attention deficit hyperactivity disorder  (ISO)
autism spectrum disorder  (ISO)
autoimmune lymphoproliferative syndrome  (ISO)
autosomal dominant polycystic kidney disease  (ISO)
bacterial meningitis  (ISO)
bacterial pneumonia  (ISO)
Behcet's disease  (ISO)
Bone Neoplasms  (ISO)
brain edema  (IEP,ISO)
brain infarction  (ISO)
Brain Injuries  (IDA,IMP,ISO)
brain ischemia  (IDA,ISO)
Breast Neoplasms  (ISO)
Bronchial Hyperreactivity  (ISO)
bronchiectasis  (ISO)
bronchiolitis obliterans  (ISO)
bronchopulmonary dysplasia  (ISO)
bullous pemphigoid  (ISO)
Burns  (IEP)
CAKUT2  (ISO)
calcinosis  (ISO)
Cardiac Fibrosis  (IEP,ISO)
Cardiomegaly  (IEP)
cardiomyopathy  (ISO)
carotid artery disease  (ISO)
Carotid Artery Injuries  (IEP)
Carotid Atherosclerosis  (ISO)
Cerebral Hemorrhage  (ISO)
cerebral infarction  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
childhood absence epilepsy  (IEP)
cholangiocarcinoma  (IEP,ISO)
cholesteatoma  (ISO)
cholesteatoma of middle ear  (ISO)
chorioamnionitis  (ISO)
Choroidal Neovascularization  (IDA,ISO)
chronic inflammatory demyelinating polyradiculoneuropathy  (ISO)
chronic obstructive pulmonary disease  (IEP,ISO)
Chronic Periodontitis  (IDA)
chronic ulcer of skin  (ISO)
Cicatrix  (IDA)
cognitive disorder  (IEP)
colon adenocarcinoma  (ISO)
Colonic Neoplasms  (IDA,IEP,ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (IEP)
congestive heart failure  (IDA,IEP,ISO)
conjunctivochalasis  (ISO)
coronary artery disease  (IEP,ISO)
crescentic glomerulonephritis  (IEP)
cystic fibrosis  (ISO)
dermatomyositis  (ISO)
Diabetic Foot  (ISO)
Diabetic Nephropathies  (IEP,ISO)
diabetic neuropathy  (ISO)
diabetic retinopathy  (ISO)
Disease Progression  (ISO)
Down syndrome  (ISO)
Duchenne muscular dystrophy  (ISO)
ductal carcinoma in situ  (ISO)
Embolism  (ISO)
Emphysema  (IEP)
endometrial carcinoma  (ISO)
endometriosis  (IEP)
epidermolysis bullosa simplex  (ISO)
epilepsy  (ISO)
esophagus adenocarcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
exfoliation syndrome  (ISO)
Experimental Arthritis  (IEP)
Experimental Autoimmune Encephalomyelitis  (IEP,ISO)
Experimental Autoimmune Neuritis  (IEP)
Experimental Colitis  (IEP)
Experimental Diabetes Mellitus  (IEP,ISO)
Experimental Liver Cirrhosis  (ISO)
Experimental Liver Neoplasms  (IEP)
Experimental Mammary Neoplasms  (IEP,ISO)
extrahepatic cholestasis  (ISO)
facial paralysis  (ISO)
familial hyperlipidemia  (ISO)
Febrile Seizures  (ISO)
Fibrosis  (IEP)
Focal Cortical Dysplasia of Taylor  (ISO)
focal epilepsy  (IEP,ISO)
focal segmental glomerulosclerosis  (IEP)
fragile X syndrome  (ISO)
galactosialidosis  (ISO)
gastric ulcer  (IEP,ISO)
glaucoma  (ISO)
glioblastoma  (ISO)
glomerulosclerosis  (IDA,IEP)
Gouty Arthritis  (ISO)
heart valve disease  (ISO)
Hemorrhagic Shock  (IEP)
hepatic veno-occlusive disease  (IEP)
hepatocellular carcinoma  (ISO)
Herpes Simplex Encephalitis  (ISO)
Human Influenza  (ISO)
Huntington's disease  (IEP)
hyperglycemia  (IEP)
hyperhomocysteinemia  (ISO)
Hyperlipoproteinemia Type II  (ISO)
Hyperoxia  (IEP,ISO)
Hyperoxic Lung Injury  (ISO)
Hyperplasia  (ISO)
hypertension  (IEP,ISO)
hypertrophic cardiomyopathy  (ISO)
ileus  (IEP)
Inflammation  (ISO)
interstitial lung disease  (ISO)
intracranial aneurysm  (IDA,IEP,ISO)
ischemia  (ISO)
Kawasaki disease  (ISO)
kidney disease  (IEP)
Laryngeal Neoplasms  (ISO)
Lead Poisoning  (ISO)
liver disease  (ISO)
Liver Injury  (IEP)
Liver Reperfusion Injury  (IEP)
lung disease  (IMP,ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
Lung Reperfusion Injury  (IEP)
lupus nephritis  (ISO)
lymphangioleiomyomatosis  (ISO)
Lymphatic Metastasis  (ISO)
macular degeneration  (ISO)
malignant astrocytoma  (ISO)
Malignant Pleural Effusions  (ISO)
mandibuloacral dysplasia type A lipodystrophy  (ISO)
Marfan syndrome  (ISO)
membranous glomerulonephritis  (IEP)
meningococcal meningitis  (IEP)
metabolic dysfunction-associated steatohepatitis  (ISO)
Metaphyseal Anadysplasia  (ISO)
Metaphyseal Anadysplasia 2  (ISO)
middle cerebral artery infarction  (IEP,ISO)
morphine dependence  (ISO)
Multiple Organ Failure  (IEP,ISO)
multiple sclerosis  (ISO)
Mycoplasma Infections  (IEP)
myocardial infarction  (IDA,IEP,ISO)
myocarditis  (ISO)
Nasal Polyps  (ISO)
Neointima  (IEP,ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (IEP,IMP,ISO)
Neoplastic Cell Transformation  (ISO)
Nephrogenic Fibrosing Dermopathy  (ISO)
neuroblastoma  (ISO)
neuromyelitis optica  (ISO)
obesity  (ISO)
obstructive sleep apnea  (ISO)
ocular hypertension  (IEP)
oral submucous fibrosis  (ISO)
osteoarthritis  (ISO)
osteoporosis  (ISO)
pancreatic cancer  (ISO)
pancreatic ductal carcinoma  (ISO)
paracoccidioidomycosis  (ISO)
Parkinsonism  (ISO)
Pathologic Constriction  (ISO)
Perennial Allergic Rhinitis  (ISO)
periodontitis  (ISO)
pleural tuberculosis  (ISO)
Pneumococcal Meningitis  (IEP,IMP)
pneumonia  (ISO)
polymyositis  (ISO)
Polypoidal Choroidal Vasculopathy  (ISO)
pre-eclampsia  (ISO)
Premature Birth  (ISO)
primary biliary cholangitis  (IEP)
primary open angle glaucoma  (ISO)
primary progressive multiple sclerosis  (ISO)
Prostatic Neoplasms  (ISO)
Pseudomonas Aeruginosa Keratitis  (ISO)
pterygium  (ISO)
pulmonary embolism  (IDA)
pulmonary emphysema  (IEP,ISO)
pulmonary fibrosis  (IEP,ISO)
pulmonary hypertension  (IDA,IEP,ISO)
pulmonary tuberculosis  (ISO)
pyoderma gangrenosum  (ISO)
relapsing-remitting multiple sclerosis  (ISO)
renal cell carcinoma  (ISO)
renal fibrosis  (IEP)
renal hypertension  (IDA)
Reperfusion Injury  (IMP,ISO)
Respiratory Sounds  (ISO)
respiratory syncytial virus infectious disease  (ISO)
Respirovirus Infections  (IEP)
retinal disease  (ISO)
retinal ischemia  (IEP)
rheumatic heart disease  (ISO)
rheumatoid arthritis  (ISO)
Rhinosinusitis  (ISO)
Right Ventricular Hypertrophy  (IEP)
rosacea  (ISO)
sciatic neuropathy  (IEP)
Seasonal Allergic Rhinitis  (ISO)
Sepsis  (IMP,ISO)
sinusitis  (ISO)
Sjogren's syndrome  (ISO)
skin melanoma  (ISO)
Skin Neoplasms  (ISO)
Spinal Cord Injuries  (IEP)
squamous cell carcinoma  (ISO)
Stable Angina  (ISO)
status epilepticus  (IEP)
stomach cancer  (ISO)
stomach carcinoma  (IEP)
Stroke  (IEP,ISO)
Sturge-Weber syndrome  (ISO)
Subarachnoid Hemorrhage  (IEP,ISO)
Sunburn  (ISO)
Sweet syndrome  (ISO)
systemic scleroderma  (ISO)
T-Cell Immunodeficiency, Recurrent Infections, and Autoimmunity with or without Cardiac Malformations  (ISO)
Tachycardia, Atrioventricular Nodal Reentry  (ISO)
Takayasu's arteritis  (ISO)
temporal arteritis  (ISO)
temporal lobe epilepsy  (ISO)
thoracic aortic aneurysm  (IEP,ISO)
thrombosis  (ISO)
tongue squamous cell carcinoma  (ISO)
transient cerebral ischemia  (IDA,IEP,ISO)
traumatic brain injury  (ISO)
tuberous sclerosis  (ISO)
tularemia  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (IEP,ISO)
ulcerative colitis  (ISO)
urinary bladder cancer  (ISO)
varicose veins  (ISO)
Venous Thrombosis  (HEP,ISO)
Ventilator-Induced Lung Injury  (ISO)
ventricular septal defect  (ISO)
viral encephalitis  (ISO)
withdrawal disorder  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (ISO)
(+)-Pimaric acid  (ISO)
(+)-Tetrandrine  (EXP,ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(24S)-24-hydroxycholesterol  (ISO)
(25R)-cholest-5-ene-3beta,26-diol  (ISO)
(R)-carnitine  (EXP)
(R)-noradrenaline  (EXP,ISO)
(S)-colchicine  (ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (ISO)
(S)-ropivacaine  (ISO)
1'-acetoxychavicol acetate  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (ISO)
1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane  (EXP)
1,10-phenanthroline  (EXP,ISO)
1,2,3-Trichloropropane  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (EXP)
1,3-benzothiazole-2-thiol  (ISO)
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine  (ISO)
1-hydroxy-1-norresistomycin  (ISO)
1-naphthyl isothiocyanate  (ISO)
1-octadec-9-enoylglycero-3-phosphate  (ISO)
15-deoxy-Delta(12,14)-prostaglandin J2  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,2'-bipyridine  (ISO)
2,2,2-trichloroethanol  (ISO)
2,3,3',4,4',5,5'-Heptachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (EXP)
2,4-diaminotoluene  (ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2-acetamidofluorene  (EXP)
2-amino-2-deoxy-D-glucopyranose  (EXP,ISO)
2-Amino-5-nitrophenol  (ISO)
2-deoxy-D-glucose  (ISO)
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid  (ISO)
2-hydroxypropanoic acid  (ISO)
2-methoxy-1,4-naphthoquinone  (ISO)
2-palmitoylglycerol  (ISO)
2-trans,6-trans,10-trans-geranylgeranyl diphosphate  (EXP,ISO)
2-trans,6-trans-farnesyl diphosphate  (EXP)
26-hydroxycholesterol  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,3',5,5'-tetraiodothyroacetic acid  (ISO)
3,3'-diindolylmethane  (ISO)
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid  (ISO)
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methyladenine  (ISO)
3-methylcholanthrene  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-Aminobenzamide  (ISO)
4-hydroxy-17beta-estradiol  (ISO)
4-hydroxy-TEMPO  (EXP)
4-hydroxyhexenal  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-nitroquinoline N-oxide  (ISO)
5,6alpha-epoxy-5alpha-cholestan-3beta-ol  (EXP)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
5-chloro-7-iodoquinolin-8-ol  (ISO)
5-fluorouracil  (ISO)
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP,ISO)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (ISO)
7-ketocholesterol  (EXP,ISO)
7-nitroindazole  (ISO)
7alpha-hydroxycholesterol  (ISO)
[6]-Shogaol  (ISO)
A-967079  (ISO)
abacavir  (ISO)
acetaldehyde  (ISO)
acetic acid  (EXP)
acetylcholine  (ISO)
acetylsalicylic acid  (EXP,ISO)
acrolein  (ISO)
acrylamide  (ISO)
actinomycin D  (ISO)
aflatoxin B1  (ISO)
agomelatine  (EXP)
AH23848  (ISO)
AICA ribonucleotide  (ISO)
alachlor  (EXP)
aldehydo-D-glucosamine  (EXP,ISO)
aldehydo-D-glucose  (EXP,ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinyl palmitate  (EXP)
allethrin  (ISO)
allopurinol  (ISO)
alloxanthine  (ISO)
allyl isothiocyanate  (ISO)
alpha-D-galactose  (EXP)
alpha-mangostin  (ISO)
alpha-naphthoflavone  (EXP,ISO)
alpha-Zearalanol  (EXP)
alternariol  (ISO)
Altertoxin II  (ISO)
aluminium atom  (EXP,ISO)
aluminium oxide  (ISO)
aluminium(0)  (EXP,ISO)
aminoguanidine  (EXP)
amitrole  (ISO)
ammonium chloride  (EXP)
anagliptin  (ISO)
anandamide  (ISO)
andrographolide  (ISO)
anethole  (ISO)
anthocyanin  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (EXP,ISO)
antirheumatic drug  (ISO)
antroquinonol  (ISO)
apigenin  (ISO)
apocynin  (EXP,ISO)
arachidonic acid  (ISO)
arecoline  (EXP)
aristolochic acid A  (ISO)
aristolochic acids  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
artesunate  (EXP,ISO)
ascofuranone  (EXP,ISO)
astragaloside IV  (EXP)
atorvastatin calcium  (EXP,ISO)
ATP  (EXP,ISO)
atrazine  (ISO)
azetidine  (ISO)
Azoxymethane  (EXP,ISO)
Bacoside a  (EXP)
baicalein  (ISO)
BAPTA  (ISO)
beclomethasone  (ISO)
benazepril  (EXP,ISO)
benomyl  (EXP,ISO)
benzalkonium chloride  (EXP,ISO)
benzamide  (ISO)
benzene  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzofurans  (ISO)
benzyl acetate  (ISO)
berberine  (ISO)
Bergenin  (ISO)
beta-aminopropionitrile  (EXP)
beta-D-glucosamine  (EXP,ISO)
beta-hexachlorocyclohexane  (ISO)
beta-naphthoflavone  (ISO)
betulinic acid  (ISO)
biochanin A  (ISO)
biphenyl-2-ol  (ISO)
bis(2-chloroethyl) sulfide  (EXP,ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisdemethoxycurcumin  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol A diglycidyl ether  (EXP)
bisphenol AF  (ISO)
bisphenol F  (ISO)
Bisphenol P  (ISO)
bitertanol  (ISO)
bleomycin A2  (EXP,ISO)
bortezomib  (ISO)
BQ 123  (ISO)
budesonide  (EXP)
bufalin  (ISO)
buta-1,3-diene  (ISO)
butanal  (ISO)
butane-2,3-dione  (ISO)
butein  (ISO)
Butylbenzyl phthalate  (ISO)
C.I. Natural Red 20  (ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
calcitriol  (ISO)
calcium dichloride  (EXP,ISO)
camptothecin  (ISO)
candesartan  (EXP)
cannabidiol  (ISO)
cantharidin  (ISO)
capillarisin  (ISO)
capsaicin  (ISO)
captopril  (ISO)
carbamazepine  (ISO)
carbendazim  (ISO)
carbon atom  (ISO)
carbon monoxide  (ISO)
carbon nanotube  (ISO)
carrageenan  (EXP)
carvacrol  (EXP)
carvedilol  (EXP,ISO)
carvone  (ISO)
casticin  (EXP,ISO)
CEDRELONE  (ISO)
celastrol  (EXP)
celecoxib  (EXP,ISO)
ceric oxide  (ISO)
CGS-21680  (ISO)
chalcones  (ISO)
chelerythrine  (ISO)
chitin  (ISO)
chitosan  (ISO)
chloroprene  (ISO)
chloroquine  (ISO)
chlorothalonil  (ISO)
chlorpromazine  (ISO)
choline  (ISO)
chromium(6+)  (ISO)
chrysin  (ISO)
Cinnamyl anthranilate  (ISO)
ciprofloxacin  (EXP)
Cirsimarin  (ISO)
cisplatin  (EXP,ISO)
clarithromycin  (EXP)
clofibrate  (ISO)
clopidogrel  (EXP)
cobalt atom  (ISO)
cocaine  (EXP,ISO)
coenzyme Q10  (EXP)
cordycepin  (ISO)
corosolic acid  (ISO)
cortisol  (ISO)
coumarin  (ISO)
crocidolite asbestos  (ISO)
crotonaldehyde  (ISO)
Cuprizon  (EXP)
curcumin  (EXP,ISO)
cycloastragenol  (ISO)
cycloprothrin  (ISO)
cyclosporin A  (ISO)
cyhalothrin  (ISO)
cypermethrin  (ISO)
cysteamine  (ISO)
cytochalasin D  (ISO)
D-glucose  (EXP,ISO)
daidzein  (EXP)
dapsone  (ISO)
deguelin  (ISO)
delphinidin  (ISO)
demethoxycurcumin  (ISO)
Deoxyschizandrin  (ISO)
desferrioxamine B  (ISO)
Destruxin B  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diallyl disulfide  (ISO)
Diallyl sulfide  (EXP,ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dibenziodolium  (EXP,ISO)
Dibutyl phosphate  (ISO)
dibutyl phthalate  (EXP,ISO)
dichlorine  (ISO)
dichloromethane  (ISO)
dicoumarol  (ISO)
Dictamnine  (ISO)
dieckol  (ISO)
dieldrin  (EXP)
diepoxybutane  (EXP)
diethyl phthalate  (ISO)
dihydroartemisinin  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dimethyl sulfoxide  (EXP,ISO)
dimethylarsinic acid  (EXP,ISO)
dimethylarsinous acid  (ISO)
diosgenin  (EXP,ISO)
dioxygen  (EXP,ISO)
disodium selenite  (EXP,ISO)
disulfiram  (ISO)
divanadium pentaoxide  (ISO)
dizocilpine maleate  (EXP)
donepezil hydrochloride  (ISO)
doxorubicin  (EXP,ISO)
doxycycline  (EXP,ISO)
EC 3.1.1.4 (phospholipase A2) inhibitor  (ISO)
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor  (ISO)
edaravone  (EXP)
elemental carbon  (ISO)
elemental selenium  (ISO)
ellagic acid  (ISO)
embelin  (ISO)
emetine  (ISO)
endosulfan  (EXP,ISO)
entinostat  (ISO)
erlotinib hydrochloride  (ISO)
ethanol  (EXP,ISO)
Ethyl pyruvate  (ISO)
ethylparaben  (ISO)
etodolac  (ISO)
eugenol  (EXP,ISO)
everolimus  (ISO)
Evodiamine  (ISO)
excitatory amino acid agonist  (ISO)
famotidine  (EXP)
farnesyl diphosphate  (EXP)
farrerol  (EXP)
fasudil  (ISO)
febuxostat  (EXP)
fenbendazole  (ISO)
fenofibrate  (ISO)
fentanyl  (EXP)
fenvalerate  (EXP)
ferric oxide  (EXP)
Fexofenadine hydrochloride  (ISO)
fingolimod hydrochloride  (ISO)
fisetin  (ISO)
flavonoids  (EXP,ISO)
flucythrinate  (ISO)
fluoxetine  (EXP,ISO)
flurbiprofen  (ISO)
flutamide  (EXP)
fluvalinate  (ISO)
fluvastatin  (ISO)
folic acid  (EXP,ISO)
formononetin  (ISO)
formoterol fumarate  (EXP)
fosinopril  (EXP)
fructose  (ISO)
fucoidan  (ISO)
fulvestrant  (ISO)
fumigaclavine C  (ISO)
gadolinium trichloride  (EXP)
galactose  (EXP)
galangin  (ISO)
galaxolide  (ISO)
gallic acid  (EXP,ISO)
Garcinol  (ISO)
gatifloxacin  (EXP)
gefitinib  (EXP,ISO)
gemcitabine  (ISO)
Genipin  (ISO)
genistein  (EXP,ISO)
geraniol  (EXP)
GGTI-2133  (EXP)
gingerol  (ISO)
Ginkgoic acid  (ISO)
ginsenoside C-K  (ISO)
ginsenoside Rg1  (EXP)
Glabrene  (ISO)
glucagon  (ISO)
glucose  (EXP,ISO)
glutathione  (ISO)
glycitein  (ISO)
glycyrrhetinate  (ISO)
glycyrrhetinic acid  (ISO)
glycyrrhizinic acid  (ISO)
Goe 6976  (ISO)
gold atom  (ISO)
gold(0)  (ISO)
graphene oxide  (ISO)
graphite  (EXP)
guggulsterone  (ISO)
GW 501516  (ISO)
heparin  (ISO)
heptachlor  (EXP)
hesperidin  (EXP,ISO)
hexachlorobenzene  (EXP,ISO)
hexadecanoic acid  (ISO)
hexanal  (ISO)
high-density lipoprotein cholesterol  (ISO)
hinokiflavone  (ISO)
homocysteine  (EXP,ISO)
hyaluronic acid  (ISO)
hydrogen peroxide  (ISO)
hydrogen sulfide  (EXP)
hydroquinone  (ISO)
hydroxamic acid  (ISO)
hydroxysafflor yellow A  (EXP,ISO)
hydroxytyrosol  (ISO)
ibuprofen  (EXP,ISO)
icariin  (EXP)
ICI 118551  (ISO)
idebenone  (EXP)
idelalisib  (ISO)
ifosfamide  (ISO)
imiquimod  (ISO)
indinavir  (EXP)
indole-3-methanol  (ISO)
indometacin  (EXP,ISO)
ipratropium  (EXP)
irbesartan  (EXP)
irigenin  (ISO)
irinotecan  (ISO)
iron atom  (ISO)
iron dextran  (ISO)
iron(0)  (ISO)
Isoliensinine  (ISO)
isoliquiritigenin  (ISO)
isoprenaline  (EXP,ISO)
isotretinoin  (ISO)
JTE-013  (ISO)
juglone  (ISO)
kaempferol  (ISO)
kainic acid  (ISO)
L-ascorbic acid  (ISO)
L-methionine  (ISO)
lead diacetate  (ISO)
letrozole  (ISO)
leukotriene B4  (ISO)
leukotriene C4  (ISO)
leukotriene D4  (ISO)
leuprolide  (EXP)
Liensinine  (ISO)
linalool  (ISO)
linoleic acid  (EXP,ISO)
lipoarabinomannan  (ISO)
lipopolysaccharide  (EXP,ISO)
liquiritigenin  (EXP)
liquiritin  (EXP)
lithocholic acid  (ISO)
LLY-507  (ISO)
loliolide  (ISO)
lomefloxacin  (EXP)
lonafarnib  (ISO)
losartan  (EXP,ISO)
lovastatin  (ISO)
luteolin  (ISO)
LY294002  (EXP,ISO)
Magnolol  (ISO)
manganese(II) chloride  (EXP)
mangiferin  (ISO)
mechlorethamine  (EXP,ISO)
medroxyprogesterone acetate  (ISO)
melatonin  (EXP,ISO)
melittin  (ISO)
menadione  (ISO)
mercury atom  (ISO)
mercury dichloride  (EXP)
mercury(0)  (ISO)
metformin  (ISO)
methamphetamine  (ISO)
Methanandamide  (ISO)
methotrexate  (EXP,ISO)
methyl caffeate  (ISO)
methylglyoxal  (ISO)
methylmercury chloride  (EXP)
metoprolol  (ISO)
mevalonic acid  (ISO)
microcystin-LR  (EXP,ISO)
mifepristone  (EXP,ISO)
minocycline  (EXP,ISO)
miquelianin  (ISO)
mono(2-ethylhexyl) phthalate  (EXP,ISO)
monobenzyl phthalate  (ISO)
Monobutylphthalate  (ISO)
monocrotaline  (EXP,ISO)
morin  (EXP,ISO)
morphine  (ISO)
Morroniside  (ISO)
morusin  (ISO)
moxifloxacin  (EXP,ISO)
myricetin  (ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (ISO)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (EXP,ISO)
N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide  (ISO)
N-acetyl-L-cysteine  (EXP,ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (EXP)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
N-tosyl-L-phenylalanyl chloromethyl ketone  (ISO)
N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine  (EXP)
naloxone  (ISO)
Nandrolone decanoate  (EXP)
naphthalene  (ISO)
naringin  (EXP,ISO)
Neferine  (ISO)
nerolidol  (EXP)
nickel atom  (ISO)
nickel dichloride  (ISO)
nickel sulfate  (ISO)
niclosamide  (ISO)
nicotinamide  (ISO)
nicotine  (ISO)
nifedipine  (ISO)
nimesulide  (ISO)
nitric oxide  (ISO)
nitrites  (ISO)
nitrobenzenes  (EXP)
nitrogen dioxide  (ISO)
nitroglycerin  (ISO)
nobiletin  (EXP)
Nonidet P-40  (ISO)
Nonylphenol  (ISO)
NORCANTHARIDIN  (ISO)
norfloxacin  (EXP)
NS-398  (ISO)
O-(chloroacetylcarbamoyl)fumagillol  (ISO)
ochratoxin A  (EXP,ISO)
oleanolic acid  (ISO)
oleic acid  (ISO)
oleuropein  (ISO)
Ophiopogonin D  (ISO)
oridonin  (ISO)
oroxylin A  (ISO)
osthole  (ISO)
ouabain  (ISO)
oxaliplatin  (EXP)
oxidopamine  (ISO)
oxybutynin  (ISO)
oxytocin  (EXP)
ozone  (ISO)
p-cresol  (ISO)
paclitaxel  (EXP,ISO)
Paeonol  (EXP)
palmatine  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
parthenolide  (ISO)
pentetrazol  (EXP)
perfluorooctane-1-sulfonic acid  (EXP,ISO)
perfluorooctanoic acid  (EXP,ISO)
perindopril  (EXP)
phenanthrolines  (EXP)
phenethyl caffeate  (EXP,ISO)
phenethyl isothiocyanate  (ISO)
phenylarsine oxide  (ISO)
phenylephrine  (ISO)
PhIP  (ISO)
phloretin  (EXP)
phorbol 12,13-dibutanoate  (ISO)
phorbol 13-acetate 12-myristate  (EXP,ISO)
phosgene  (EXP)
pioglitazone  (ISO)
piperine  (ISO)
pipoxolan  (ISO)
pirfenidone  (ISO)
platycodin D  (EXP,ISO)
plumbagin  (ISO)
pravastatin  (EXP)
prednisolone  (EXP)
pregnenolone 16alpha-carbonitrile  (ISO)
probucol  (ISO)
progesterone  (EXP,ISO)
propiconazole  (ISO)
propranolol  (ISO)
propylparaben  (ISO)
prostaglandin E2  (ISO)
prostaglandin F2alpha  (ISO)
protein kinase inhibitor  (ISO)
Ptaquiloside  (ISO)
pterostilbene  (ISO)
pyrrolidine dithiocarbamate  (ISO)
quercetin  (EXP,ISO)
quercetin 3-O-beta-D-galactopyranoside  (ISO)
quercetin 3-O-beta-D-glucofuranoside  (ISO)
quercetin 3-O-beta-D-glucopyranoside  (ISO)
quinpirole  (ISO)
rac-lactic acid  (ISO)
raloxifene  (EXP,ISO)
ranitidine  (EXP)
raspberry ketone  (EXP)
razoxane  (EXP)
reactive oxygen species  (ISO)
rebaudioside A  (EXP,ISO)
regorafenib  (ISO)
reparixin  (ISO)
resveratrol  (EXP,ISO)
riboflavin  (ISO)
rolipram  (ISO)
rosmarinic acid  (EXP)
rotenone  (ISO)
rottlerin  (ISO)
roxarsone  (ISO)
ruthenium atom  (EXP)
rutin  (ISO)
Salinomycin  (ISO)
sanguinarine  (ISO)
saxagliptin  (EXP)
SB 203580  (EXP,ISO)
SB 290157  (ISO)
scoparone  (ISO)
selenium atom  (ISO)
selumetinib  (ISO)
senecionine  (ISO)
serpentine asbestos  (ISO)
sevoflurane  (EXP,ISO)
Shikonin  (ISO)
sildenafil citrate  (ISO)
silibinin  (ISO)
silicon dioxide  (EXP,ISO)
simazine  (ISO)
simvastatin  (EXP,ISO)
sirolimus  (EXP,ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (ISO)
sodium fluoride  (ISO)
sodium hydroxide  (EXP)
sodium silicate  (EXP)
solasodine  (ISO)
Solithromycin  (ISO)
Soman  (EXP)
sotorasib  (ISO)
sparfloxacin  (EXP)
sphingosine 1-phosphate  (ISO)
staurosporine  (ISO)
steviol  (ISO)
stevioside  (ISO)
streptozocin  (EXP,ISO)
succimer  (ISO)
sulfasalazine  (EXP,ISO)
sulfur dioxide  (ISO)
sunitinib  (EXP)
T-2 toxin  (EXP,ISO)
tamoxifen  (EXP,ISO)
tanespimycin  (ISO)
Tanshinone I  (ISO)
taraxasterol  (ISO)
taurine  (EXP)
taurocholic acid  (ISO)
tebuconazole  (ISO)
telmisartan  (EXP)
temozolomide  (ISO)
tephrosin  (ISO)
terbinafine  (ISO)
tert-butyl hydroperoxide  (ISO)
tetracaine  (ISO)
tetrachloromethane  (EXP,ISO)
tetracyclines  (EXP)
tetrahydrocurcumin  (ISO)
tetrahydropalmatine  (ISO)
tetramethylpyrazine  (ISO)
thalidomide  (ISO)
Theaflavin 3,3'-digallate  (ISO)
thioacetamide  (EXP,ISO)
thymol  (ISO)
thymol sulfate(1-)  (ISO)
thymoquinone  (ISO)
thyroxine  (ISO)
Tiron  (ISO)
titanium atom  (ISO)
titanium dioxide  (ISO)
tofacitinib  (ISO)
toluene 2,4-diisocyanate  (ISO)
tomatidine  (ISO)
topotecan  (EXP)
trametinib  (ISO)
trans-anethole  (ISO)
trans-cinnamic acid  (ISO)
triadimefon  (ISO)
tributylstannane  (ISO)
tricetin  (ISO)
trichloroethene  (ISO)
trichostatin A  (ISO)
triclosan  (ISO)
triphenyl phosphate  (ISO)
Triptolide  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
tropisetron  (EXP)
tungsten  (ISO)
Tungsten carbide  (ISO)
tyrphostin AG 1478  (ISO)
ubiquinone-0  (ISO)
urethane  (ISO)
ursodeoxycholic acid  (EXP)
ursolic acid  (EXP,ISO)
Ursonic acid  (ISO)
valproic acid  (EXP,ISO)
valsartan  (EXP,ISO)
varespladib methyl  (ISO)
venlafaxine hydrochloride  (EXP)
vitamin D  (ISO)
vorinostat  (EXP,ISO)
VX nerve agent  (ISO)
WIN 55212-2  (ISO)
wogonin  (EXP,ISO)
wortmannin  (EXP,ISO)
xanthohumol  (ISO)
Y-27632  (ISO)
zafirlukast  (ISO)
zerumbone  (ISO)
zidovudine  (EXP)
zileuton  (EXP)
zinc atom  (EXP,ISO)
zinc oxide  (EXP,ISO)
zinc protoporphyrin  (ISO)
zinc sulfate  (ISO)
zinc(0)  (EXP,ISO)
zingiberene  (EXP)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
apoptotic process  (IEA,ISO)
cell migration  (IEA,ISO)
cellular response to cell-matrix adhesion  (IEP,IMP)
cellular response to cytokine stimulus  (IEP)
cellular response to interleukin-1  (IEP)
cellular response to iron(III) ion  (IEP)
cellular response to lipopolysaccharide  (IEP)
cellular response to low-density lipoprotein particle stimulus  (IEP)
cellular response to tumor necrosis factor  (IEP)
cellular response to UV-A  (IEA,ISO)
collagen catabolic process  (IBA,IDA,IEA,ISO)
embryo implantation  (IEA,ISO)
endodermal cell differentiation  (IEA,ISO)
extracellular matrix organization  (IBA,IEA,ISO)
heart development  (IDA)
kidney development  (IEP)
macrophage chemotaxis  (IDA)
modification of synaptic structure, modulating synaptic transmission  (EXP,IDA)
negative regulation of apoptotic process  (IEA,ISO)
negative regulation of cation channel activity  (ISO)
negative regulation of epithelial cell differentiation involved in kidney development  (IEA,ISO)
negative regulation of fibroblast proliferation  (IMP)
negative regulation of intrinsic apoptotic signaling pathway  (IEA,ISO)
ossification  (IEP)
parturition  (IEP)
positive regulation of angiogenesis  (IMP)
positive regulation of apoptotic process  (IEA,ISO)
positive regulation of epidermal growth factor receptor signaling pathway  (IEA,ISO)
positive regulation of keratinocyte migration  (IEA,ISO)
positive regulation of leukocyte migration  (IDA)
positive regulation of protein phosphorylation  (ISO)
positive regulation of release of cytochrome c from mitochondria  (IEA,ISO)
positive regulation of synaptic plasticity  (IMP)
positive regulation of vascular associated smooth muscle cell proliferation  (IEA,ISO)
protein catabolic process  (IDA)
proteolysis  (IDA,IEA,ISO,ISS)
regulation of postsynaptic neurotransmitter receptor diffusion trapping  (IDA)
response to amyloid-beta  (IEA,ISO)
response to estradiol  (IEP)
response to ethanol  (IEP)
response to high light intensity  (IEP)
response to hyperoxia  (IEP)
response to hypoxia  (IEP)
response to lipopolysaccharide  (IEP)
response to mechanical stimulus  (IEP)
response to nicotine  (IEP)
response to nutrient  (IEP)
response to oxidative stress  (IDA)
response to retinoic acid  (IEP)
response to tumor necrosis factor  (IEP)
response to vitamin A  (IEP)
response to xenobiotic stimulus  (IDA,IEP)
skeletal system development  (IEA,ISO)
symbiont-mediated transformation of host cell  (IDA)
tissue remodeling  (IDA)

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Abe S, etal., Blood Purif. 2010;29(4):321-6. Epub 2010 Feb 24.
2. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Afonso AA, etal., Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2506-12.
3. Lack of matrix metalloproteinase-9 worsens ventilator-induced lung injury. Albaiceta GM, etal., Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L535-43. Epub 2008 Jan 25.
4. Downregulation of remodelling enzymatic activity induced by an angiotensin-converting enzyme inhibitor (perindopril) reduces the degeneration of experimental abdominal aortic aneurysms in a rat model. Alsac JM, etal., Eur J Vasc Endovasc Surg. 2011 Apr;41(4):474-80. doi: 10.1016/j.ejvs.2010.12.007. Epub 2011 Jan 20.
5. Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification. Alvarez J, etal., J Bone Miner Res. 2005 Jun;20(6):1011-21. Epub 2005 Feb 7.
6. The role of AdipoR1 and AdipoR2 in liver fibrosis. Alzahrani B, etal., Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):700-708. doi: 10.1016/j.bbadis.2017.12.012. Epub 2017 Dec 10.
7. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Andersen GN, etal., Respir Med. 2007 Oct;101(10):2199-206. Epub 2007 Jul 20.
8. Genetic variations in MMP9 and MMP13 contribute to tooth agenesis in a Brazilian population. Antunes LS, etal., J Oral Sci. 2013;55(4):281-6.
9. Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms. Aoki T, etal., Stroke. 2007 Aug;38(8):2337-45. Epub 2007 Jun 14.
10. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Aoki T, etal., Stroke. 2007 Jan;38(1):162-9. Epub 2006 Nov 22.
11. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Arnold S, etal., Exp Biol Med (Maywood). 2008 Jul;233(7):860-73. Epub 2008 Apr 29.
12. Upregulated expression and activation of membrane‑associated proteases in esophageal squamous cell carcinoma. Augoff K, etal., Oncol Rep. 2014 Jun;31(6):2820-6. doi: 10.3892/or.2014.3162. Epub 2014 Apr 29.
13. Matrix metalloproteinase-9 genetic variation and primary angle closure glaucoma in a Caucasian population. Awadalla MS, etal., Mol Vis. 2011;17:1420-4. Epub 2011 May 27.
14. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Babykutty S, etal., Clin Exp Metastasis. 2012 Jun;29(5):471-92. doi: 10.1007/s10585-012-9464-6. Epub 2012 Mar 15.
15. Protective effect of naringenin in experimental ischemic stroke: down-regulated NOD2, RIP2, NF-¿B, MMP-9 and up-regulated claudin-5 expression. Bai X, etal., Neurochem Res. 2014 Aug;39(8):1405-15. doi: 10.1007/s11064-014-1326-y. Epub 2014 May 20.
16. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Barichello T, etal., Exp Biol Med (Maywood). 2014 Feb;239(2):225-31. doi: 10.1177/1535370213508354. Epub 2014 Jan 13.
17. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Basile DP, etal., Am J Physiol Renal Physiol 2004 May;286(5):F893-902. Epub 2004 Jan 6.
18. Effects of two conventional preoperative radiation schedules on anastomotic healing in the rat colon. Bedirli A, etal., Eur Surg Res. 2007;39(3):141-7. Epub 2007 Mar 2.
19. MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Beeghly-Fadiel A, etal., Breast Cancer Res Treat. 2011 Apr;126(2):507-13. doi: 10.1007/s10549-010-1119-1. Epub 2010 Aug 20.
20. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Beliveau A, etal., Genes Dev. 2010 Dec 15;24(24):2800-11. doi: 10.1101/gad.1990410.
21. The involvement of oxidants and NF-kappaB in cytokine-induced MMP-9 synthesis by bone marrow-derived osteoprogenitor cells. Ben-David D, etal., Inflamm Res. 2012 Jul;61(7):673-88. doi: 10.1007/s00011-012-0461-7. Epub 2012 Mar 13.
22. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Beranek M, etal., Mol Vis. 2008 Jun 14;14:1114-21.
23. Postnatal ablation of Foxm1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling. Bolte C, etal., PLoS One. 2012;7(11):e48713. doi: 10.1371/journal.pone.0048713. Epub 2012 Nov 8.
24. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Bolton CE, etal., Chron Respir Dis. 2009;6(2):81-7.
25. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Bousserouel S, etal., Int J Oncol. 2010 Jun;36(6):1485-90.
26. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Boz C, etal., Clin Neurol Neurosurg. 2006 Feb;108(2):124-8.
27. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. Bozdagi O, etal., J Neurophysiol. 2007 Jul;98(1):334-44. Epub 2007 May 9.
28. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Breen DM, etal., Atherosclerosis. 2012 Jun;222(2):375-81. Epub 2012 Mar 27.
29. Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. Brito VGB, etal., Front Pharmacol. 2020 Nov 11;11:579926. doi: 10.3389/fphar.2020.579926. eCollection 2020.
30. Markers of myocardial damage, tissue healing, and inflammation after radiofrequency catheter ablation of atrial tachyarrhythmias. Brueckmann M, etal., J Cardiovasc Electrophysiol. 2004 Jun;15(6):686-91.
31. Stromal remodelling is required for progressive involution of the rat ventral prostate after castration: Identification of a matrix metalloproteinase-dependent apoptotic wave. Bruni-Cardoso A, etal., Int J Androl. 2009 Nov 10.
32. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Bu DX, etal., Am J Pathol. 2006 Dec;169(6):2245-53.
33. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. Camp TM, etal., J Hypertens 2003 Sep;21(9):1719-27.
34. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. Candelario-Jalil E, etal., J Pharmacol Exp Ther. 2007 Nov;323(2):488-98. Epub 2007 Aug 17.
35. Metalloproteinase-9 in circulating monocytes in pulmonary hypertension. Cantini-Salignac C, etal., Fundam Clin Pharmacol. 2006 Aug;20(4):405-10.
36. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. Cauwe B, etal., J Autoimmun. 2011 May;36(3-4):239-52. doi: 10.1016/j.jaut.2011.02.002. Epub 2011 Mar 3.
37. The activities of MMP-9 and total gelatinase respond differently to substrate coating and cyclic mechanical stretching in fibroblasts and myoblasts. Cha MC and Purslow PP, Cell Biol Int. 2010 Apr 21;34(6):587-91.
38. Remodeling of experimental arteriovenous fistula with increased matrix metalloproteinase expression in rats. Chan CY, etal., J Vasc Surg. 2007 Apr;45(4):804-11.
39. Iatrogenic extracellular matrix disruption as a local trigger for postoperative ileus. Chang J, etal., J Surg Res. 2012 Dec;178(2):632-9. doi: 10.1016/j.jss.2012.05.044. Epub 2012 Jun 1.
40. Baicalein protects against retinal ischemia by antioxidation, antiapoptosis, downregulation of HIF-1alpha, VEGF, and MMP-9 and upregulation of HO-1. Chao HM, etal., J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):539-49. doi: 10.1089/jop.2012.0179. Epub 2013 Mar 28.
41. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. Chau KY, etal., Eye (Lond). 2007 Dec;21(12):1511-5. Epub 2007 Feb 16.
42. The alterations of matrix metalloproteinase-9 in mouse brainstem during herpes simplex virus type 1-induced facial palsy. Chen D, etal., J Mol Neurosci. 2013 Nov;51(3):703-9. doi: 10.1007/s12031-013-0051-3. Epub 2013 Jul 2.
43. A single nucleotide polymorphism in the matrix metalloproteinase 9 gene (-8202A/G) is associated with thoracic aortic aneurysms and thoracic aortic dissection. Chen L, etal., J Thorac Cardiovasc Surg. 2006 May;131(5):1045-52.
44. Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats. Chen Y, etal., Eur Respir J. 2010 Apr;35(4):904-12. Epub 2009 Nov 6.
45. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Chen Y, etal., Front Biosci. 2006 Sep 1;11:3121-8.
46. [Effect of curcumin on activity of matrix metalloproteinase 2, 9 and nuclear expression of RelA in rat hepatic stellate cells by activating peroxisome proliferator-activated receptor gamma signal] Cheng Y, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 May;27(5):439-43.
47. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Chetty A, etal., Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L584-92. Epub 2008 Jul 25.
48. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cheung C, etal., Cardiovasc Pathol. 2006 Mar-Apr;15(2):63-74.
49. Matrix metalloproteinase gelatinase B (MMP-9) is associated with leaking glaucoma filtering blebs. Chintala SK, etal., Exp Eye Res. 2005 Oct;81(4):429-36.
50. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Cho HJ, etal., Carcinogenesis. 2007 May;28(5):1104-10. Epub 2006 Nov 17.
51. Increased expression of matrix metalloproteinase 9 and tubulin-alpha in pulmonary sclerosing hemangioma. Cho SJ, etal., Oncol Rep. 2007 Nov;18(5):1139-44.
52. Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. Christopoulos TA, etal., Oncol Rep. 2007 Oct;18(4):855-60.
53. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Chu CS, etal., Am J Cardiol. 2006 Mar 1;97(5):646-50. Epub 2006 Jan 9.
54. The clinical significance of gelatinase B in gouty arthritis of the knee. Chu SC, etal., Clin Chim Acta. 2004 Jan;339(1-2):77-83.
55. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Chua PK, etal., Clin Diagn Lab Immunol. 2003 Mar;10(2):308-14.
56. Regulation of collagen degradation in the rat myocardium after infarction. Cleutjens JP, etal., J Mol Cell Cardiol. 1995 Jun;27(6):1281-92.
57. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Copin JC, etal., Eur J Neurosci. 2005 Oct;22(7):1597-608.
58. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. Cotignola J, etal., BMC Med Genet. 2007 Mar 8;8:10.
59. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Coussens LM, etal., Cell. 2000 Oct 27;103(3):481-90.
60. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. Cox MB, etal., Mult Scler. 2013 Sep;19(10):1268-74. doi: 10.1177/1352458513475493. Epub 2013 Feb 11.
61. Chorioamnionitis and increased neonatal lung lavage fluid matrix metalloproteinase-9 levels: implications for antenatal origins of chronic lung disease. Curley AE, etal., Am J Obstet Gynecol. 2003 Apr;188(4):871-5.
62. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. Dahiya S, etal., J Immunol. 2011 Sep 1;187(5):2723-31. doi: 10.4049/jimmunol.1101342. Epub 2011 Aug 1.
63. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood-brain barrier dysfunction in an animal model of severe sepsis. Dal-Pizzol F, etal., Mol Neurobiol. 2013 Aug;48(1):62-70. doi: 10.1007/s12035-013-8433-7. Epub 2013 Mar 12.
64. Deficiency of ataxia telangiectasia mutated kinase delays inflammatory response in the heart following myocardial infarction. Daniel LL, etal., J Am Heart Assoc. 2014 Dec;3(6):e001286. doi: 10.1161/JAHA.114.001286.
65. Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence. Davelaar AL, etal., Scand J Gastroenterol. 2015 Mar;50(3):321-32. doi: 10.3109/00365521.2014.940379. Epub 2015 Jan 6.
66. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Davies PL, etal., Thorax. 2010 Mar;65(3):246-51.
67. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Derosa G, etal., Diabetes Metab. 2007 Apr;33(2):129-34. Epub 2007 Feb 22.
68. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Derosa G, etal., Endothelium. 2006 May-Jun;13(3):227-31.
69. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Descamps FJ, etal., Exp Eye Res. 2006 Aug;83(2):401-7. Epub 2006 Apr 27.
70. Steroid-independent upregulation of matrix metalloproteinase 9 in chronic rhinosinusitis patients with radiographic evidence of osteitis. Detwiller KY, etal., Int Forum Allergy Rhinol. 2013 May;3(5):364-8. doi: 10.1002/alr.21135. Epub 2013 Feb 8.
71. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions. Di Carlo A, etal., Oncol Rep. 2007 Aug;18(2):425-31.
72. Mechanisms involved in the development and healing of diabetic foot ulceration. Dinh T, etal., Diabetes. 2012 Nov;61(11):2937-47. doi: 10.2337/db12-0227. Epub 2012 Jun 11.
73. The outer wall of small airways is a major site of remodeling in fatal asthma. Dolhnikoff M, etal., J Allergy Clin Immunol. 2009 May;123(5):1090-7, 1097.e1. Epub 2009 Apr 10.
74. LINC00689 participates in proliferation, chemoresistance and metastasis via miR-31-5p/YAP/β-catenin axis in colorectal cancer. Du YL, etal., Exp Cell Res. 2020 Oct 1;395(1):112176. doi: 10.1016/j.yexcr.2020.112176. Epub 2020 Jul 16.
75. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. Dubois B, etal., J Neurol. 2003 Sep;250(9):1037-43.
76. Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Dumont O, etal., Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):317-24. Epub 2006 Dec 7.
77. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease. Duran-Vilaregut J, etal., Neuropathol Appl Neurobiol. 2011 Aug;37(5):525-37. doi: 10.1111/j.1365-2990.2010.01157.x.
78. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. Eberhardt W, etal., J Biol Chem 2002 Sep 6;277(36):33518-28.
79. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Ebihara I, etal., Am J Kidney Dis. 1998 Oct;32(4):544-50.
80. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Ebrahem Q, etal., Am J Pathol. 2010 Jan;176(1):496-503. Epub 2009 Nov 30.
81. Sequential in-office vitreous aspirates demonstrate vitreous matrix metalloproteinase 9 levels correlate with the amount of subretinal fluid in eyes with wet age-related macular degeneration. Ecker SM, etal., Mol Vis. 2012;18:1658-67. Epub 2012 Jun 20.
82. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eissa S, etal., Eur Urol. 2007 Nov;52(5):1388-96. Epub 2007 Apr 10.
83. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. El Messal M, etal., Clin Chim Acta. 2006 Apr;366(1-2):185-9. Epub 2005 Nov 8.
84. Matrix metalloproteases in bronchoalveolar lavage fluid of patients with type III Pseudomonas aeruginosa pneumonia. El-Solh AA, etal., J Infect. 2009 Jul;59(1):49-55. Epub 2009 May 23.
85. Matrix metalloproteinase-9 promoter gene polymorphism (-1562C>T) in nasal polyposis. Erbek SS, etal., Am J Rhinol Allergy. 2009 Nov-Dec;23(6):568-70.
86. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Ergul A, etal., Am J Hypertens. 2004 Sep;17(9):775-82.
87. Bronchoalveolar lavage MMP-9 and TIMP-1 in preschool wheezers and their relationship to persistent wheeze. Erlewyn-Lajeunesse MD, etal., Pediatr Res. 2008 Aug;64(2):194-9.
88. Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway. Esteve PO, etal., Biochem Biophys Res Commun 2002 Aug 30;296(4):864-9.
89. Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. Esteve PO, etal., J Biol Chem 2002 Sep 20;277(38):35150-5.
90. Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications. Fan HX, etal., J Exp Clin Cancer Res. 2012 Oct 29;31:90. doi: 10.1186/1756-9966-31-90.
91. MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. Fang L, etal., J Neurol Sci. 2010 Jul 15;294(1-2):51-6. doi: 10.1016/j.jns.2010.04.005. Epub 2010 May 4.
92. Increased muscle proteolysis after local trauma mainly reflects macrophage-associated lysosomal proteolysis. Farges MC, etal., Am J Physiol Endocrinol Metab 2002 Feb;282(2):E326-35.
93. The study of ISO induced heart failure rat model. Feng W and Li W, Exp Mol Pathol. 2010 Apr;88(2):299-304. Epub 2009 Nov 10.
94. Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease. Feng W, etal., Kidney Int. 2023 Oct;104(4):740-753. doi: 10.1016/j.kint.2023.06.031. Epub 2023 Jul 7.
95. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients. Fernandez Bello I, etal., Thromb Haemost. 2012 Jan;107(1):88-98. doi: 10.1160/TH11-08-0556. Epub 2011 Nov 24.
96. MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Fiotti N, etal., Atherosclerosis. 2005 Oct;182(2):287-92. Epub 2005 Feb 12.
97. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Foronjy R, etal., Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1149-57. Epub 2008 Apr 11.
98. The influence of functional polymorphisms in matrix metalloproteinase 9 on survival of breast cancer patients in a Chinese population. Fu F, etal., DNA Cell Biol. 2013 May;32(5):274-82. doi: 10.1089/dna.2012.1928. Epub 2013 Apr 9.
99. Losartan alleviates renal fibrosis by down-regulating HIF-1a and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. Fu W, etal., Ren Fail. 2012;34(10):1297-304. doi: 10.3109/0886022X.2012.723775. Epub 2012 Sep 24.
100. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Funayama H, etal., Circ J. 2004 May;68(5):451-4.
101. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Gagne PJ, etal., Am J Pathol. 2005 Nov;167(5):1349-59.
102. Long Non-coding RNA MALAT1/microRNA-143/VEGFA Signal Axis Modulates Vascular Endothelial Injury-Induced Intracranial Aneurysm. Gao G, etal., Nanoscale Res Lett. 2020 Jun 29;15(1):139. doi: 10.1186/s11671-020-03357-2.
103. Dynamic changes of matrix metalloproteinases in rat liver during the development of diethylnitrosamine-induced hepatocarcinoma. Gao Y, etal., Di Yi Jun Yi Da Xue Xue Bao 2002 Oct;22(10):865-8.
104. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
105. Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model. Geng L, etal., Exp Mol Pathol. 2010 Aug;89(1):72-81. Epub 2010 May 26.
106. Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice. George J and D'Armiento J, J Hypertens. 2011 Feb;29(2):299-308.
107. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Gianella A, etal., Am J Pathol. 2007 Apr;170(4):1165-77.
108. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Gkogkas CG, etal., Cell Rep. 2014 Dec 11;9(5):1742-55. doi: 10.1016/j.celrep.2014.10.064. Epub 2014 Nov 26.
109. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Glowinska-Olszewska B and Urban M, Metabolism. 2007 Jun;56(6):799-805.
110. Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Gonzalez-Avila G, etal., Pathobiology. 1998;66(5):196-204.
111. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Grandgirard D, etal., Antimicrob Agents Chemother. 2007 Jun;51(6):2173-8. Epub 2007 Mar 19.
112. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Gress TM, etal., Int J Cancer. 1995 Aug 9;62(4):407-13.
113. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Grigoryev DN, etal., Transl Res. 2008 Apr;151(4):197-207. Epub 2008 Feb 1.
114. Rapamycin alleviates brain edema after focal cerebral ischemia reperfusion in rats. Guo W, etal., Immunopharmacol Immunotoxicol. 2014 Jun;36(3):211-23. doi: 10.3109/08923973.2014.913616. Epub 2014 Apr 29.
115. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma] Guo W, etal., Zhonghua Fu Chan Ke Za Zhi. 2002 Oct;37(10):604-7.
116. Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. Gupta S, etal., Sci Rep. 2015 Nov 19;5:16811. doi: 10.1038/srep16811.
117. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Hanemaaijer R, etal., Matrix Biol. 1998 Dec;17(8-9):657-65.
118. Gene expression profiling of skin and draining lymph nodes of rats affected with cutaneous contact hypersensitivity. Hartmann B, etal., Inflamm Res. 2006 Aug;55(8):322-34.
119. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. Henke PK, etal., J Immunol. 2006 Sep 1;177(5):3388-97.
120. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Herpel E, etal., Histopathology. 2006 May;48(6):736-47.
121. Adrenomedullin production is increased in colorectal adenocarcinomas; its relation to matrix metalloproteinase-9. Hikosaka T, etal., Peptides. 2011 Sep;32(9):1825-31. doi: 10.1016/j.peptides.2011.07.012. Epub 2011 Aug 3.
122. Airway remodelling in children with cystic fibrosis. Hilliard TN, etal., Thorax. 2007 Dec;62(12):1074-80. Epub 2007 May 25.
123. Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. Hindi SM, etal., PLoS One. 2013 Aug 15;8(8):e72121. doi: 10.1371/journal.pone.0072121. eCollection 2013.
124. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Horne BD, etal., Am Heart J. 2007 Oct;154(4):751-8.
125. Hyperoxia decreases matrix metalloproteinase-9 and increases tissue inhibitor of matrix metalloproteinase-1 protein in the newborn rat lung: association with arrested alveolarization. Hosford GE, etal., Pediatr Res. 2004 Jul;56(1):26-34. Epub 2004 May 5.
126. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. Hosokawa T, etal., J Neuroimmunol. 2011 Jul;236(1-2):81-6. doi: 10.1016/j.jneuroim.2011.04.009. Epub 2011 May 31.
127. Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung granulomatous fibrosis caused by Angiostrongylus cantonensis. Hsu CC and Lai SC, Int J Exp Pathol. 2007 Dec;88(6):437-43.
128. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Hua J and Muschel RJ, Cancer Res. 1996 Nov 15;56(22):5279-84.
129. Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome. Hulkkonen J, etal., Rheumatology (Oxford). 2004 Dec;43(12):1476-9. Epub 2004 Aug 17.
130. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage. Hultstrom M, etal., Nephrol Dial Transplant. 2008 Mar;23(3):896-903. Epub 2007 Oct 31.
131. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Ichiyama T, etal., Pediatr Infect Dis J. 2007 Jun;26(6):542-4.
132. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Ikonomidis JS, etal., Circulation. 2006 Jul 4;114(1 Suppl):I365-70.
133. Interleukin-1beta enhanced action of kinins on extracellular matrix of spontaneous hypertensive rat cardiac fibroblasts. Imai C, etal., Clin Exp Hypertens 2005 Jan;27(1):59-69.
134. Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis. Inoue H, etal., J Hum Genet. 2012 Mar;57(3):176-83. doi: 10.1038/jhg.2011.148. Epub 2012 Jan 12.
135. Imidapril inhibits cerebral aneurysm formation in an angiotensin-converting enzyme-independent and matrix metalloproteinase-9-dependent manner. Ishibashi R, etal., Neurosurgery. 2012 Mar;70(3):722-30. doi: 10.1227/NEU.0b013e3182326188.
136. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Ishihara T, etal., Circ J. 2013;77(2):477-83. Epub 2012 Oct 26.
137. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Itagaki H, etal., Int J Clin Exp Pathol. 2013 Nov 15;6(12):2683-96. eCollection 2013.
138. Nerve growth factor metabolic dysfunction in Down's syndrome brains. Iulita MF, etal., Brain. 2014 Mar;137(Pt 3):860-72. doi: 10.1093/brain/awt372. Epub 2014 Feb 11.
139. Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. Jacob-Ferreira AL, etal., Eur J Pharmacol. 2010 Feb 10;627(1-3):216-22. Epub 2009 Oct 30.
140. Myelin loss associated with neuroinflammation in hypertensive rats. Jalal FY, etal., Stroke. 2012 Apr;43(4):1115-22. doi: 10.1161/STROKEAHA.111.643080. Epub 2012 Feb 23.
141. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Jan YY, etal., Ann Surg. 2004 Jul;240(1):89-94.
142. Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. Jang JW, etal., J Neurol Sci. 2012 Dec 15;323(1-2):221-7. doi: 10.1016/j.jns.2012.09.021. Epub 2012 Oct 7.
143. MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. Jia F, etal., J Neurotrauma. 2014 Jul 1;31(13):1225-34. doi: 10.1089/neu.2013.3230. Epub 2014 Jun 3.
144. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Joergensen MT, etal., Anticancer Res. 2010 Feb;30(2):587-92.
145. Matrix metalloproteinases are down-regulated in rat lenses exposed to oxidative stress. John M, etal., Exp Eye Res. 2004 Dec;79(6):839-46.
146. Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Jonas JB, etal., Acta Ophthalmol. 2012 Aug;90(5):e381-8. doi: 10.1111/j.1755-3768.2012.02414.x. Epub 2012 Apr 10.
147. Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells. Joo MK, etal., Int J Oncol. 2015;46(6):2380-8. doi: 10.3892/ijo.2015.2935. Epub 2015 Mar 26.
148. Douchi (fermented Glycine max Merr.) alleviates atopic dermatitis-like skin lesions in NC/Nga mice by regulation of PKC and IL-4. Jung AR, etal., BMC Complement Altern Med. 2016 Oct 24;16(1):416.
149. Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD. Kadziela-Olech H, etal., Eur Child Adolesc Psychiatry. 2015 Jan;24(1):55-63. doi: 10.1007/s00787-014-0533-z. Epub 2014 Mar 17.
150. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Kamada H, etal., Stroke. 2007 Mar;38(3):1044-9. Epub 2007 Feb 1.
151. Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice. Kandagaddala LD, etal., Exp Toxicol Pathol. 2012 Jan;64(1-2):109-14. doi: 10.1016/j.etp.2010.07.002. Epub 2010 Aug 31.
152. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Karakoc GB, etal., Pediatr Pulmonol. 2009 Oct;44(10):1010-6.
153. Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1alpha and VEGF. Kaur J and Sanyal SN, Mol Carcinog. 2011 Jan 25. doi: 10.1002/mc.20736.
154. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. Kelly BC, etal., J Am Acad Dermatol. 2010 Sep;63(3):483-9. doi: 10.1016/j.jaad.2009.09.006.
155. Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. Khandoga A, etal., J Leukoc Biol. 2006 Jun;79(6):1295-305. Epub 2006 Mar 21.
156. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome. Kieseier BC, etal., Ann Neurol. 1998 Apr;43(4):427-34.
157. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Kieseier BC, etal., Brain. 1998 Jan;121 ( Pt 1):159-66.
158. Differential expression of matrix metalloproteinases in bacterial meningitis. Kieseier BC, etal., Brain. 1999 Aug;122 ( Pt 8):1579-87.
159. Expression of specific matrix metalloproteinases in inflammatory myopathies. Kieseier BC, etal., Brain. 2001 Feb;124(Pt 2):341-51.
160. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury. Kim JH, etal., Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L580-7. Epub 2006 May 12.
161. Serum cytokines markers in toluene diisocyanate-induced asthma. Kim JH, etal., Respir Med. 2011 Mar 23.
162. Matrix metalloproteinase-9 in cerebral aneurysms. Kim SC, etal., Neurosurgery. 1997 Sep;41(3):642-66; discussion 646-7.
163. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Kim WU, etal., Arthritis Res Ther. 2005;7(1):R71-9. Epub 2004 Nov 10.
164. Immunohistochemical changes in matrix metalloproteinase-2 and 9 during small bowel allograft rejection in rats. Kimizuka K, etal., Transplant Proc 2002 May;34(3):1047-8.
165. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Knittel T, etal., Histochem Cell Biol. 2000 Jun;113(6):443-53.
166. Long-term Alcohol Consumption Increases Pro-Matrix Metalloproteinase-9 Levels via Oxidative Stress. Koken T, etal., J Med Toxicol. 2010 Apr 20.
167. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae Kong L, etal., Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Oct;28(5):717-20.
168. Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA. Konopacki FA, etal., Neuroscience. 2007 Nov 30;150(1):31-9. Epub 2007 Aug 30.
169. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Konopka A, etal., Epilepsy Res. 2013 Mar;104(1-2):45-58. doi: 10.1016/j.eplepsyres.2012.09.018. Epub 2012 Nov 23.
170. [Polymorphism in promoter regions of matrix metalloproteinases (MMP1, MMP9, and MMP12) in chronic obstructive pulmonary disease patients]. Korytina GF, etal., Genetika. 2008 Feb;44(2):242-9.
171. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Kosano H, etal., Life Sci. 1999;64(25):2307-15.
172. Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Kowluru RA, etal., Diabetes. 2011 Nov;60(11):3023-33. doi: 10.2337/db11-0816. Epub 2011 Sep 20.
173. Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Kremer R, etal., Br J Cancer. 2010 Mar 30;102(7):1180-4. Epub 2010 Mar 9.
174. Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. Kundu S, etal., Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1365-78. doi: 10.1152/ajpendo.00604.2012. Epub 2013 Apr 30.
175. Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. La Russa A, etal., J Neuroimmunol. 2010 Aug 25;225(1-2):175-9. doi: 10.1016/j.jneuroim.2010.04.016. Epub 2010 May 14.
176. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Lakka SS, etal., Oncogene. 2002 Nov 14;21(52):8011-9.
177. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Lambert V, etal., Am J Pathol. 2002 Oct;161(4):1247-53.
178. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Lau AC, etal., Arthritis Rheum. 2008 Mar;58(3):854-63. doi: 10.1002/art.23225.
179. Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia. Lausch E, etal., Am J Hum Genet. 2009 Aug;85(2):168-78. doi: 10.1016/j.ajhg.2009.06.014. Epub 2009 Jul 16.
180. Melissa officinalis extract inhibits laser-induced choroidal neovascularization in a rat model. Lee EK, etal., PLoS One. 2014 Oct 14;9(10):e110109. doi: 10.1371/journal.pone.0110109. eCollection 2014.
181. 17ß-estradiol inhibits MMP-9 and SUR1/TrpM4 expression and activation and thereby attenuates BSCB disruption/hemorrhage after spinal cord injury in male rats. Lee JY, etal., Endocrinology. 2015 May;156(5):1838-50. doi: 10.1210/en.2014-1832. Epub 2015 Mar 12.
182. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Lee SD, etal., Clin Chim Acta. 2006 May;367(1-2):62-8. Epub 2006 Jan 9.
183. Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Lee SY, etal., Respiration. 2010;80(2):133-8. Epub 2010 Feb 16.
184. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Lee WJ, etal., Glia 2003 Jan;41(1):15-24.
185. 92-kDa gelatinase (matrix metalloproteinase-9) is induced in rat amnion immediately prior to parturition. Lei H, etal., Biol Reprod. 1995 Aug;53(2):339-44.
186. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Leppert D, etal., Neurology. 1999 Jul 13;53(1):62-70.
187. MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex. Lettner T, etal., PLoS One. 2013 Jul 19;8(7):e70123. doi: 10.1371/journal.pone.0070123. Print 2013.
188. The role of matrix metalloproteinases in extracellular matrix remodelling in chronic obstructive pulmonary disease rat models Li H, etal., Zhonghua Nei Ke Za Zhi 2002 Jun;41(6):393-8.
189. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Li HC, etal., Breast Cancer Res Treat. 2004 Nov;88(1):75-85.
190. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Li S, etal., Brain Res. 2012 May 9;1453:46-55. doi: 10.1016/j.brainres.2012.03.009. Epub 2012 Mar 12.
191. Effect of respiratory syncytial virus on the activity of matrix metalloproteinase in mice. Li W and Shen HH, Chin Med J (Engl). 2007 Jan 5;120(1):5-11.
192. [Retinoic acid diminished the expression of lung tissue matrix metalloproteinase-2 and matrix metalloproteinase-9 in hyperoxia-exposed premature rats through regulating mitogen-activated protein kinases]. Li WB, etal., Zhonghua Er Ke Za Zhi. 2008 May;46(5):347-53.
193. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Li X, etal., Int J Clin Exp Pathol. 2015 Jun 1;8(6):7247-53. eCollection 2015.
194. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis. Li X, etal., J Allergy Clin Immunol. 2010 May;125(5):1061-8. Epub 2010 Apr 14.
195. [Effects of unfractionated heparin on expression of metalloproteinase-2 and -9 in acute lung injury rats]. Li X, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Oct;24(10):608-11.
196. Expression of RECK gene and MMP-9 in hilar cholangiocarcinoma and its clinical significance. Li Y, etal., J Huazhong Univ Sci Technolog Med Sci. 2005;25(5):552-4.
197. Ginkgolic acid (GA) suppresses gastric cancer growth by inducing apoptosis and suppressing STAT3/JAK2 signaling regulated by ROS. Liang JR and Yang H, Biomed Pharmacother. 2020 May;125:109585. doi: 10.1016/j.biopha.2019.109585. Epub 2020 Feb 25.
198. Activin A contributes to the development of hyperoxia-induced lung injury in neonatal mice. Lim R, etal., Pediatr Res. 2015 Jun;77(6):749-56. doi: 10.1038/pr.2015.46. Epub 2015 Mar 11.
199. Functional polymorphisms in matrix metalloproteinases-1, -3, -9 are associated with arteriovenous fistula patency in hemodialysis patients. Lin CC, etal., Clin J Am Soc Nephrol. 2010 Oct;5(10):1805-14. doi: 10.2215/CJN.01500210. Epub 2010 Jul 8.
200. [Effects of matrix metallopeptidase 9 on the proliferation, apoptosis, type I and III procollagen synthesis of rat dermal fibroblasts]. Lin DZ, etal., Zhonghua Yi Xue Za Zhi. 2012 Feb 28;92(8):564-7.
201. Expression of reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase 9 in middle ear squamous cell carcinoma. Liu X, etal., ORL J Otorhinolaryngol Relat Spec. 2012;74(1):16-21. doi: 10.1159/000334243. Epub 2011 Dec 16.
202. [Influence of periodontal therapy on serum interleukin-6 and carotid metalloproteinases in animals with chronic periodontitis associated with atherosclerosis]. Liu Y, etal., Zhonghua Kou Qiang Yi Xue Za Zhi. 2014 Mar;49(3):155-60.
203. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. Liu Z, etal., J Exp Med. 1998 Aug 3;188(3):475-82.
204. [Overexpression of IL-8 and MMP-9 confer high malignant phenotype in patients with non-small cell lung cancer]. Liu Z, etal., Zhongguo Fei Ai Za Zhi. 2010 Aug 20;13(8):795-802.
205. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Lorenzl S, etal., Int Psychogeriatr. 2008 Feb;20(1):67-76. Epub 2007 Aug 15.
206. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Lorenzl S, etal., Neuromolecular Med. 2004;5(2):119-32.
207. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome. Lovelace JW, etal., Neurobiol Dis. 2016 May;89:126-35. doi: 10.1016/j.nbd.2016.02.002. Epub 2016 Feb 2.
208. Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. Lukkarinen H, etal., Am J Respir Cell Mol Biol. 2009 Jul;41(1):59-68. Epub 2008 Dec 18.
209. Traditional Chinese medicine Kang Xian Fu Fang I is effective for prophylaxis and treatment of alcoholic liver disease in rats. Lv XH, etal., Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):182-7.
210. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. Machado DE, etal., J Exp Clin Cancer Res. 2010 Jan 19;29:4.
211. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. Machado LS, etal., BMC Neurosci. 2006 Jul 17;7:56.
212. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Maeda S, etal., Kidney Int. 2001 Oct;60(4):1428-34.
213. Increased cellular iron levels affect matrix metalloproteinase expression and phagocytosis in activated microglia. Mairuae N, etal., Neurosci Lett. 2011 Aug 1;500(1):36-40. doi: 10.1016/j.neulet.2011.06.001. Epub 2011 Jun 12.
214. Inhibition of matrix metalloproteinase on hepatic transforming growth factor beta1 and caspase-3 activation in hemorrhage. Maitra SR, etal., Acad Emerg Med. 2005 Sep;12(9):797-803. doi: 10.1197/j.aem.2005.04.017.
215. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. Malik M, etal., J Immunol. 2007 Jan 15;178(2):1013-20.
216. Matrix metalloproteinases and their impact on sinusal extension in chronic rhinosinusitis with nasal polyps. Malinsky RR, etal., Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1345-8. doi: 10.1007/s00405-012-2219-9. Epub 2012 Oct 12.
217. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Manabe S, etal., Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4747-53.
218. Coordinated elevation of membrane type 1-matrix metalloproteinase and matrix metalloproteinase-2 expression in rat uterus during postpartum involution. Manase K, etal., Reprod Biol Endocrinol. 2006 Jun 2;4:32.
219. Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Manikandan P, etal., Life Sci. 2010 Apr 29.
220. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Mao JT, etal., Chest. 2003 Nov;124(5):1724-32.
221. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. Mao JW, etal., World J Gastroenterol. 2012 Dec 21;18(47):7063-9. doi: 10.3748/wjg.v18.i47.7063.
222. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Martin MD, etal., Cancer Res. 2008 Aug 1;68(15):6251-9. doi: 10.1158/0008-5472.CAN-08-0537.
223. Increased presence of matrix metalloproteinases 2 and 9 in short- and long-term experimental herpes simplex virus encephalitis. Martinez-Torres FJ, etal., Neurosci Lett. 2004 Sep 30;368(3):274-8.
224. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Marzano AV, etal., Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):451-60.
225. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. Matsuyama Y, etal., J Surg Oncol. 2002 Jun;80(2):105-10.
226. Matrix metalloproteinase-9 amplifies the immune response to Pseudomonas aeruginosa corneal infection. McClellan SA, etal., Invest Ophthalmol Vis Sci. 2006 Jan;47(1):256-64.
227. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. McMillan JI, etal., J Clin Invest. 1996 Feb 15;97(4):1094-101.
228. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Medina C, etal., Am J Physiol Gastrointest Liver Physiol 2003 Jan;284(1):G116-22.
229. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Medley TL, etal., Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1479-84. Epub 2004 Jun 10.
230. Altered lymphocyte trafficking and diminished airway reactivity in transgenic mice expressing human MMP-9 in a mouse model of asthma. Mehra D, etal., Am J Physiol Lung Cell Mol Physiol. 2010 Feb;298(2):L189-96. Epub 2009 Nov 25.
231. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Mendes O, etal., Clin Exp Metastasis. 2005;22(3):237-46.
232. Identification of a calcium-dependent matrix metalloproteinase complex in rat chorioallantoid membranes during labour. Meraz-Cruz N, etal., Mol Hum Reprod. 2006 Oct;12(10):633-41. Epub 2006 Aug 25.
233. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
234. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. Michaluk P, etal., J Neurosci. 2009 May 6;29(18):6007-12.
235. Polymorphisms in matrix metalloproteinases MMP1 and MMP9 are associated with primary open-angle and angle closure glaucoma in a Pakistani population. Micheal S, etal., Mol Vis. 2013;19:441-7. Epub 2013 Feb 20.
236. Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Mirowska-Guzel D, etal., J Neuroimmunol. 2009 Sep 29;214(1-2):113-7. doi: 10.1016/j.jneuroim.2009.06.014. Epub 2009 Jul 22.
237. Microscopical evaluation of extracellular matrix and its relation to the palatopharyngeal muscle in obstructive sleep apnea. Molina FD, etal., Microsc Res Tech. 2010 Sep 10.
238. Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. Moore C, etal., Am J Pathol. 2007 Feb;170(2):567-77.
239. Small airway remodeling in acute respiratory distress syndrome: a study in autopsy lung tissue. Morales MM, etal., Crit Care. 2011 Jan 6;15(1):R4.
240. Role of functional single nucleotide polymorphisms of MMP1, MMP2, and MMP9 in open angle glaucomas. Mossbock G, etal., Mol Vis. 2010 Aug 28;16:1764-70.
241. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Mroczko B, etal., Pancreas. 2009 Aug;38(6):613-8.
242. Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: a potential mechanism for ischemia induced MMP activation. Muhs BE, etal., J Surg Res. 2004 Apr;117(2):249-54.
243. Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Murugan RS, etal., Anticancer Res. 2009 Jun;29(6):2301-5.
244. Expression of matrix metalloproteinase-9 associated with ets-1 proto-oncogene in rat tubulointerstitial cells. Naito T, etal., Nephrol Dial Transplant. 2005 Nov;20(11):2333-48. Epub 2005 Jul 26.
245. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Nakamura T, etal., Am J Nephrol. 2000 Jan-Feb;20(1):32-6.
246. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Nakamura T, etal., Neoplasia. 2007 Nov;9(11):979-86.
247. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. Nakano A, etal., J Neurosurg. 1995 Aug;83(2):298-307.
248. Epigenetic regulation of aortic remodeling in hyperhomocysteinemia. Narayanan N, etal., FASEB J. 2014 Aug;28(8):3411-22. doi: 10.1096/fj.14-250183. Epub 2014 Apr 16.
249. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
250. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. Nelissen I, etal., J Neuroimmunol. 2000 Jun 1;105(1):58-63.
251. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I, etal., Eur J Neurol. 2010 Feb;17(2):226-31. doi: 10.1111/j.1468-1331.2009.02775.x. Epub 2009 Oct 1.
252. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Nikkola J, etal., Clin Cancer Res. 2005 Jul 15;11(14):5158-66.
253. Matrix metalloproteinases with gelatinolytic activity induced by Paracoccidioides brasiliensis infection. Nishikaku AS, etal., Int J Exp Pathol. 2009 Oct;90(5):527-37. doi: 10.1111/j.1365-2613.2009.00663.x.
254. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Nomura S, etal., Eur Surg Res. 2005 Nov-Dec;37(6):370-8.
255. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. O'Brien J, etal., Am J Pathol. 2010 Mar;176(3):1241-55. Epub 2010 Jan 28.
256. Matrix metalloproteinases in blood from patients with LAM. Odajima N, etal., Respir Med. 2009 Jan;103(1):124-9. Epub 2008 Aug 29.
257. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Ohnishi S, etal., Stem Cells. 2007 May;25(5):1166-77. Epub 2007 Feb 8.
258. Angiotensin II Enhances Interleukin-1beta-Induced MMP-9 Secretion in Adult Rat Cardiac Fibroblasts. Okada M, etal., J Vet Med Sci. 2010 Feb 9.
259. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
260. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. Onodera S, etal., J Biol Chem 2002 Mar 8;277(10):7865-74.
261. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. Pannu H, etal., J Neurosurg. 2006 Sep;105(3):418-23.
262. Visible light induces matrix metalloproteinase-9 expression in rat eye. Papp AM, etal., J Neurochem. 2007 Dec;103(6):2224-33. Epub 2007 Sep 11.
263. Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. Park JA, etal., J Korean Med Sci. 2005 Aug;20(4):607-11.
264. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Park KP, etal., Stroke. 2009 Aug;40(8):2836-42. Epub 2009 Jun 25.
265. Serum MMP-2 and MMP-9 in patients with Behcet's disease: do their higher levels correlate to vasculo-Behcet's disease associated with aneurysm formation? Pay S, etal., Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S70-5.
266. Effect of experimental genital mycoplasmosis on production of matrix metalloproteinases in membranes and amniotic fluid of Sprague-Dawley rats. Peltier MR, etal., Am J Reprod Immunol. 2007 Feb;57(2):116-21.
267. At low doses ethanol maintains blood-brain barrier (BBB) integrity after hypoxia and reoxygenation: a brain slice study. Peng C, etal., Neurol Res. 2013 Oct;35(8):790-7. doi: 10.1179/1743132813Y.0000000198. Epub 2013 Apr 12.
268. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Peterson JT, etal., Circulation. 2001 May 8;103(18):2303-9.
269. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Pilcher BK, etal., Ann N Y Acad Sci. 1999 Jun 30;878:12-24.
270. MMP-9 gene variants increase the risk for non-atopic asthma in children. Pinto LA, etal., Respir Res. 2010 Feb 24;11:23.
271. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
272. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
273. Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Plaks V, etal., Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11109-14. doi: 10.1073/pnas.1309561110. Epub 2013 Jun 17.
274. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Planas AM, etal., Neurobiol Dis. 2001 Oct;8(5):834-46.
275. Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Pollanen PJ, etal., Atherosclerosis. 2005 May;180(1):73-8. Epub 2004 Dec 18.
276. Atrial extracellular matrix remodelling in patients with atrial fibrillation. Polyakova V, etal., J Cell Mol Med. 2008 Jan-Feb;12(1):189-208. doi: 10.1111/j.1582-4934.2008.00219.x. Epub 2008 Jan 10.
277. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Popov Y, etal., Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G323-34. doi: 10.1152/ajpgi.00394.2009. Epub 2010 Jan 7.
278. Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. Pradeepkumar Singh L, etal., Free Radic Biol Med. 2007 Jul 15;43(2):289-99. Epub 2007 Apr 29.
279. Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Pryczynicz A, etal., Folia Histochem Cytobiol. 2007;45(1):37-40.
280. Morphological changes of cerebral vessels and expression patterns of MMP-2 and MMP-9 on cerebrovascular wall of alcoholic rats. Qi Q, etal., Int J Clin Exp Pathol. 2014 Apr 15;7(5):1880-8. eCollection 2014.
281. [Regulatory effects of inhaled steroids on expression of matrix metalloproteinase-9 and its inhibitor in asthmatic rats] Qiao HM, etal., Zhonghua Er Ke Za Zhi. 2005 Aug;43(8):591-4.
282. Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Qin YH, etal., Pediatr Nephrol. 2009 Aug;24(8):1477-86. Epub 2009 Apr 9.
283. Temperospatial expression of matrix metalloproteinases 1, 2, 3, and 9 during early tooth development. Randall LE and Hall RC, Connect Tissue Res 2002;43(2-3):205-11.
284. Embryogenesis of the rat heart: the expression of collagenases. Ratajska A and Cleutjens JP, Basic Res Cardiol. 2002 May;97(3):189-97.
285. Identification of neutrophil activation markers as novel surrogate markers of CF lung disease. Rath T, etal., PLoS One. 2014 Dec 29;9(12):e115847. doi: 10.1371/journal.pone.0115847. eCollection 2014.
286. MMP9 overexpression is associated with good surgical outcome in children with UPJO: Preliminary results. Reis ST, etal., BMC Urol. 2016 Jul 23;16(1):44. doi: 10.1186/s12894-016-0162-6.
287. LncRNA H19 regulates smooth muscle cell functions and participates in the development of aortic dissection through sponging miR-193b-3p. Ren M, etal., Biosci Rep. 2021 Jan 29;41(1):BSR20202298. doi: 10.1042/BSR20202298.
288. GOA pipeline RGD automated data pipeline
289. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
290. Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome. Riise GC, etal., J Heart Lung Transplant. 2010 Jul;29(7):800-7. Epub 2010 Apr 22.
291. Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis. Rodriguez-Pla A, etal., Arthritis Rheum. 2008 Jun;58(6):1849-53. doi: 10.1002/art.23457.
292. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Rodriguez-Pla A, etal., Circulation. 2005 Jul 12;112(2):264-9. Epub 2005 Jul 5.
293. Minocycline prevents dynorphin-induced neurotoxicity during neuropathic pain in rats. Rojewska E, etal., Neuropharmacology. 2014 Nov;86:301-10. doi: 10.1016/j.neuropharm.2014.08.001. Epub 2014 Aug 27.
294. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Roldan V, etal., Am Heart J. 2008 Jul;156(1):85-91.
295. Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer. Rong Z, etal., J Exp Clin Cancer Res. 2013 May 28;32:32. doi: 10.1186/1756-9966-32-32.
296. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Rosell A, etal., Stroke. 2006 Jun;37(6):1399-406. Epub 2006 May 11.
297. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. Roy LD, etal., BMC Cancer. 2011 Aug 22;11:365.
298. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Russo LA, etal., Reprod Biol Endocrinol. 2009 Nov 4;7:124.
299. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Sanders JS, etal., Am J Physiol Renal Physiol. 2007 Dec;293(6):F1927-34. Epub 2007 Sep 26.
300. Effect of glycosaminoglycans on matrix metalloproteinases in type II collagen-induced experimental arthritis. Sandya S and Sudhakaran PR, Exp Biol Med (Maywood). 2007 May;232(5):629-37.
301. [The behavior of intra-leukocyte peroxidase after irradiation with radar microwaves in intra-articular exudates]. Santolini BM, etal., Minerva Ortop. 1971 Dec;22(12):459-62.
302. Tissue remodeling in the acute otitis media mouse model. Sautter NB, etal., Int J Pediatr Otorhinolaryngol. 2011 Nov;75(11):1368-71. doi: 10.1016/j.ijporl.2011.07.026. Epub 2011 Sep 1.
303. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Schaefer L, etal., Diabetologia. 1997 Sep;40(9):1035-43.
304. Gelatinase expression and proteolytic activity in giant-cell arteritis. Segarra M, etal., Ann Rheum Dis. 2007 Nov;66(11):1429-35. Epub 2007 May 14.
305. Preferential expression of matrix metalloproteinase-9 in mouse skin after sulfur mustard exposure. Shakarjian MP, etal., J Appl Toxicol. 2006 May-Jun;26(3):239-46.
306. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Sheen P, etal., Eur Respir J. 2009 Jan;33(1):134-41. Epub 2008 Aug 20.
307. [Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro] Sheng L, etal., Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1080-4.
308. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Shigemori Y, etal., Acta Neurochir Suppl. 2006;96:130-3.
309. Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Shin CY, etal., Nitric Oxide. 2007 Jun;16(4):425-32. Epub 2007 Mar 24.
310. Nonasthmatic nasal polyposis patients with allergy exhibit greater epithelial MMP positivity. Shin HW, etal., Otolaryngol Head Neck Surg. 2009 Oct;141(4):442-7.
311. Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data. Sigala F, etal., Eur J Vasc Endovasc Surg. 2006 Sep;32(3):238-45. doi: 10.1016/j.ejvs.2006.01.026. Epub 2006 Jun 13.
312. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Simonetti O, etal., Cancer. 2002 Nov 1;95(9):1963-70.
313. The interplay of collagen IV, tumor necrosis factor-alpha, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloproteases-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Siu MK, etal., Endocrinology 2003 Jan;144(1):371-87.
314. Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma. Sivaramakrishnan V and Niranjali Devaraj S, Chem Biol Interact. 2009 Aug 14;180(3):353-9. Epub 2009 Feb 21.
315. Analysis of matrix metalloproteinase-9 gene polymorphism -1562 C/T in patients suffering from systemic sclerosis with and without ulcers. Skarmoutsou E, etal., Int J Mol Med. 2011 Jun;27(6):873-7. doi: 10.3892/ijmm.2011.661. Epub 2011 Mar 31.
316. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Sluijter JP, etal., Stroke. 2006 Jan;37(1):235-9. Epub 2005 Dec 8.
317. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Sochor M, etal., Digestion. 2009;80(2):65-73. Epub 2009 Jun 3.
318. [Expression of gelatinases A and B and their endogenous regulators in immortal and transformed fibroblasts]. Solov'eva NI, etal., Biomed Khim. 2009 Jul-Aug;55(4):441-50.
319. [MMP-9 gene -1562C/T polymorphism in aortic dissection in Chinese hypertensive patients] Song WH, etal., Zhonghua Nei Ke Za Zhi. 2006 May;45(5):376-8.
320. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Sorbi D, etal., Arthritis Rheum. 1996 Oct;39(10):1747-53.
321. L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Souza-Costa DC, etal., Chest. 2005 Nov;128(5):3705-10.
322. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Souza-Costa DC, etal., Crit Care Med. 2007 Jan;35(1):239-45.
323. Urine vascular biomarkers in Sturge-Weber syndrome. Sreenivasan AK, etal., Vasc Med. 2013 Jun;18(3):122-8. doi: 10.1177/1358863X13486312.
324. [mRNA expression analysis of metastatic markers in clear-cell renal cell carcinoma] Struckmann K, etal., Verh Dtsch Ges Pathol. 2005;89:178-83.
325. Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats. Sun H, etal., Diabetes Res Clin Pract. 2013 Apr;100(1):85-95. doi: 10.1016/j.diabres.2013.01.012. Epub 2013 Feb 4.
326. Peripheral thermal injury causes blood-brain barrier dysfunction and matrix metalloproteinase (MMP) expression in rat. Swann K, etal., Brain Res. 2007 Jan 19;1129(1):26-33. Epub 2006 Dec 6.
327. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. Szklarczyk A, etal., J Neurosci 2002 Feb 1;22(3):920-30.
328. Serum levels of matrix metalloproteinases 2 and 9 and TGFBR2 gene screening in patients with ascending aortic dilatation. Símová J, etal., Folia Biol (Praha). 2013;59(4):154-61.
329. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Takacs E, etal., Neurochem Int. 2010 May-Jun;56(6-7):799-809. doi: 10.1016/j.neuint.2010.03.003. Epub 2010 Mar 18.
330. Modulation of matrix metalloproteinase-9 in hepatic stellate cells by three-dimensional type I collagen: its activation and signaling pathway. Takahara T, etal., Hepatol Res. 2003 Aug;26(4):318-326.
331. Age-related changes in the expression of gelatinase and tissue inhibitor of metalloproteinase genes in mandibular condylar, growth plate, and articular cartilage in rats. Takahashi I, etal., J Mol Histol. 2005 Jun;36(5):355-66. Epub 2005 Oct 6.
332. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Tamaki S, etal., Intern Med. 2009;48(15):1255-62. Epub 2009 Aug 3.
333. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Tanney DC, etal., Dev Dyn. 1998 Sep;213(1):121-9.
334. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Tao ZY, etal., Life Sci. 2004 Feb 6;74(12):1561-72.
335. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Taylor JL, etal., Infect Immun. 2006 Nov;74(11):6135-44. Epub 2006 Sep 18.
336. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Tchetverikov I, etal., Ann Rheum Dis. 2004 Jul;63(7):881-3.
337. Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection. Teng L, etal., Mol Cell Biochem. 2012 Jan;360(1-2):271-7. doi: 10.1007/s11010-011-1066-0. Epub 2011 Oct 1.
338. Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction. Thibert KA, etal., PLoS One. 2012;7(11):e50430. doi: 10.1371/journal.pone.0050430. Epub 2012 Nov 21.
339. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Thieringer FR, etal., Mol Carcinog. 2012 Jun;51(6):439-48. doi: 10.1002/mc.20809. Epub 2011 Jun 16.
340. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. Tian M, etal., BMC Cancer. 2008 Aug 16;8:241.
341. IGF-II and MMP9 as surgical repair indicators of ventricular septal defects. Tsai CY, etal., Clin Chim Acta. 2011 Apr 11;412(9-10):761-5. doi: 10.1016/j.cca.2011.01.005. Epub 2011 Jan 14.
342. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Tsuji K, etal., Stroke. 2005 Sep;36(9):1954-9. Epub 2005 Jul 28.
343. Tetrahydrocurcumin ameliorates homocysteinylated cytochrome-c mediated autophagy in hyperhomocysteinemia mice after cerebral ischemia. Tyagi N, etal., J Mol Neurosci. 2012 May;47(1):128-38. doi: 10.1007/s12031-011-9695-z. Epub 2012 Jan 3.
344. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Umar S, etal., Pathol Res Pract. 2007;203(12):863-72. Epub 2007 Oct 29.
345. Decrease in serum matrix metalloproteinase-9 and matrix metalloproteinase-3 levels in Zucker fa/fa obese rats after treatment with swertiamarin. Vaidya H, etal., Exp Clin Cardiol. 2012 Spring;17(1):12-6.
346. Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer. Vaish V, etal., Cell Biochem Biophys. 2013 Jun;66(2):205-27. doi: 10.1007/s12013-012-9469-4.
347. Evaluation of molecular markers in a rat model of mammary carcinogenesis. Vinothini G, etal., Oncol Res. 2009;17(10):483-93.
348. Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome. Volman TJ, etal., J Pathol. 2004 Aug;203(4):968-75.
349. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Vukasovic I, etal., Clin Chem Lab Med. 2006;44(4):428-34.
350. Prevention of ischemia/reperfusion-induced accumulation of matrix metalloproteinases in rat lung by preconditioning with nitric oxide. Waldow T, etal., J Surg Res. 2009 Apr;152(2):198-208. Epub 2008 Apr 9.
351. Effect of Liuweibuqi capsule, a Chinese patent medicine, on the JAK1/STAT3 pathway and MMP9/TIMP1 in a chronic obstructive pulmonary disease rat model. Wang C, etal., J Tradit Chin Med. 2015 Feb;35(1):54-62.
352. [Detection of the activity of MMP2 and MMP9 in middle ear cholesteatoma]. Wang H, etal., Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2004 Oct;18(10):620-2.
353. Oxidized low-density lipoprotein-induced matrix metalloproteinase-9 expression via PKC-delta/p42/p44 MAPK/Elk-1 cascade in brain astrocytes. Wang HH, etal., Neurotox Res. 2010 Jan;17(1):50-65. Epub 2009 Jun 25.
354. The association of single nucleotide polymorphisms in the MMP-9 genes with susceptibility to acute primary angle closure glaucoma in Taiwanese patients. Wang IJ, etal., Mol Vis. 2006 Oct 26;12:1223-32.
355. [Expression of matrix metalloproteinase-2,9 in cholesteatoma from different positions]. Wang J and Yu LS, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;44(1):44-8.
356. Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction. Wang JA, etal., J Zhejiang Univ Sci B. 2006 Aug;7(8):641-7.
357. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Wang M, etal., Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6885-9.
358. Mechanisms of matrix metalloproteinase-9 upregulation and tissue destruction in various organs in influenza A virus infection. Wang S, etal., J Med Invest. 2010 Feb;57(1-2):26-34.
359. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Wang X, etal., Oncogene. 2011 Apr 21;30(16):1901-11. doi: 10.1038/onc.2010.563. Epub 2010 Dec 13.
360. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Wang XB, etal., Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19520-5. doi: 10.1073/pnas.0807248105. Epub 2008 Dec 1.
361. Idazoxan reduces blood-brain barrier damage during experimental autoimmune encephalomyelitis in mouse. Wang XS, etal., Eur J Pharmacol. 2014 Aug 5;736:70-6. doi: 10.1016/j.ejphar.2014.04.034. Epub 2014 May 2.
362. [Effects of xinfeng capsule on myocardial fibrosis in adjuvant arthritis rats and its mechanism research]. Wang Y, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 May;33(5):668-73.
363. The role of oxidative stress and inflammation in conjunctivochalasis. Ward SK, etal., Invest Ophthalmol Vis Sci. 2010 Apr;51(4):1994-2002. doi: 10.1167/iovs.09-4130. Epub 2009 Dec 17.
364. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Webb KE, etal., Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1837-44.
365. Important role of matrix metalloproteinase 9 in epileptogenesis. Wilczynski GM, etal., J Cell Biol. 2008 Mar 10;180(5):1021-35. doi: 10.1083/jcb.200708213.
366. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Wilson WR, etal., Circulation. 2006 Jan 24;113(3):438-45.
367. Time course of upregulation of inflammatory mediators in the hemorrhagic brain in rats: correlation with brain edema. Wu H, etal., Neurochem Int. 2010 Oct;57(3):248-53. Epub 2010 Jun 10.
368. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats. Wu M and Li YG, Mol Cell Biochem. 2006 Jan;282(1-2):141-6.
369. Cariporide, a specific Na/H(+) exchanger 1 blocker, inhibits neointimal proliferation induced by advanced glycation end products in a balloon injury rat model. Wu S, etal., Pharmacology. 2013;91(3-4):123-30. doi: 10.1159/000346128. Epub 2013 Jan 23.
370. Reducing scar formation by regulation of IL-1 and MMP-9 expression by using sustained release of prednisolone-loaded PDLL microspheres in a murine wound model. Wu TH, etal., J Biomed Mater Res A. 2013 Apr;101(4):1165-72. doi: 10.1002/jbm.a.34413. Epub 2012 Oct 18.
371. [Effects of ru'ai shuhou recipe on the matrix metalloproteinases and the inhibitive factors in the recurrence and metastasis of HER2 positive breast cancer]. Wu XQ, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Nov;32(11):1526-30.
372. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Wu ZS, etal., Int J Cancer. 2008 May 1;122(9):2050-6.
373. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. Xiong W, etal., J Vasc Surg. 2008 Jan;47(1):166-72; discussion 172. doi: 10.1016/j.jvs.2007.09.016.
374. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology Xu SL, etal., Zhonghua Yan Ke Za Zhi. 2009 Mar;45(3):260-5.
375. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. Xue M, etal., J Neurosci. 2006 Oct 4;26(40):10281-91.
376. Sendai virus infection up-regulates trypsin I and matrix metalloproteinase-9, triggering viral multiplication and matrix degradation in rat lungs and lung L2 cells. Yamada H, etal., Arch Virol. 2006 Dec;151(12):2529-37. Epub 2006 Jun 30.
377. Low-energy laser irradiation facilitates the velocity of tooth movement and the expressions of matrix metalloproteinase-9, cathepsin K, and alpha(v) beta(3) integrin in rats. Yamaguchi M, etal., Eur J Orthod. 2010 Apr;32(2):131-9. Epub 2010 Feb 16.
378. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. Yan AT, etal., J Card Fail. 2006 Sep;12(7):514-9.
379. Intracranial aneurysm formation in type-one diabetes rats. Yan T, etal., PLoS One. 2013 Jul 2;8(7):e67949. doi: 10.1371/journal.pone.0067949. Print 2013.
380. Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation. Yang B, etal., Kidney Int. 2014 Feb;85(2):289-306. doi: 10.1038/ki.2013.290. Epub 2013 Aug 7.
381. Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Yang DC, etal., Cardiology. 2010;116(2):133-41. doi: 10.1159/000317245. Epub 2010 Jul 1.
382. Increased expression of gelatinase (MMP-2 and MMP-9) in pterygia and pterygium fibroblasts with disease progression and activation of protein kinase C. Yang SF, etal., Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4588-96. doi: 10.1167/iovs.08-3147. Epub 2009 May 6.
383. Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats. Yao J, etal., Eur J Cardiothorac Surg. 2012 Nov;42(5):e121-7. doi: 10.1093/ejcts/ezs445.
384. Role of c-Jun N-terminal kinase in early brain injury after subarachnoid hemorrhage. Yatsushige H, etal., J Neurosci Res. 2007 May 15;85(7):1436-48.
385. Transcriptomic dissection of tongue squamous cell carcinoma. Ye H, etal., BMC Genomics. 2008 Feb 6;9:69. doi: 10.1186/1471-2164-9-69.
386. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. Ye P, etal., J Pharm Pharm Sci. 2006;9(3):365-75.
387. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer. Ye Y, etal., Tumour Biol. 2016 Mar;37(3):3185-95. doi: 10.1007/s13277-015-4100-0. Epub 2015 Oct 2.
388. Matrix metalloprotease expressions in both reperfusion lung injury and oleic acid lung injury models and the protective effects of ilomastat. Yeh DY, etal., Transplant Proc. 2009 Jun;41(5):1508-11.
389. Expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 1 in nonrecurrent vs recurrent nasal polyps. Yeo NK, etal., Ann Allergy Asthma Immunol. 2013 Sep;111(3):205-10. doi: 10.1016/j.anai.2013.06.023. Epub 2013 Jul 16.
390. Protective role of matrix metalloproteinase-9 in ozone-induced airway inflammation. Yoon HK, etal., Environ Health Perspect. 2007 Nov;115(11):1557-63.
391. Aging is associated with increased activities of matrix metalloproteinase-2 and -9 in tenocytes. Yu TY, etal., BMC Musculoskelet Disord. 2013 Jan 2;14:2. doi: 10.1186/1471-2474-14-2.
392. Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum. Yu XZ, etal., J Zhejiang Univ Sci B. 2013 Jan;14(1):68-75. doi: 10.1631/jzus.B1200112.
393. Retinoids induce MMP-9 expression through RARalpha during mammary gland remodeling. Zaragoza R, etal., Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1140-8. Epub 2006 Dec 12.
394. Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration. Zeng R, etal., Mol Vis. 2013;19:729-36. Epub 2013 Mar 21.
395. NMDA receptor-mediated activation of NADPH oxidase and glomerulosclerosis in hyperhomocysteinemic rats. Zhang C, etal., Antioxid Redox Signal. 2010 Oct 1;13(7):975-86. doi: 10.1089/ars.2010.3091.
396. [Expression of trophoblast invasion related genes mRNA and protein in human placenta in preeclampsia]. Zhang H, etal., Zhonghua Fu Chan Ke Za Zhi. 2006 Aug;41(8):509-13.
397. rAAV2-TGF-beta(3) Decreases Collagen Synthesis and Deposition in the Liver of Experimental Hepatic Fibrosis Rat. Zhang Y, etal., Dig Dis Sci. 2010 Jan 28.
398. Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis. Zhang YB, etal., Chin J Traumatol. 2010 Jun 1;13(3):188-92.
399. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Zhang Z, etal., Neuroscience. 2012 Sep 27;221:140-50. doi: 10.1016/j.neuroscience.2012.07.013. Epub 2012 Jul 16.
400. [Expression and significance of matrix metalloproteinase-1,9, tissue inhibitor of metalloproteinase-4 and extracellular matrix metalloproteinase inducer in the myocardium of congestive heart failure in patients with rheumatic heart diseases]. Zhao Y, etal., Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Aug;34(8):790-5.
401. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Zhao YG, etal., Cancer Res. 2004 Jan 15;64(2):590-8.
402. Expression of matrix metalloproteinase -2, -9 and tissue inhibitors of metalloproteinase -1, -2, -3 mRNAs in rat uterus during early pregnancy. Zhao YG, etal., Mol Reprod Dev 2002 Jun;62(2):149-58.
403. Inhibition of NF-kappaB activation by Pyrrolidine dithiocarbamate partially attenuates hippocampal MMP-9 activation and improves cognitive deficits in streptozotocin-induced diabetic rats. Zhao Z, etal., Behav Brain Res. 2013 Feb 1;238:44-7. doi: 10.1016/j.bbr.2012.10.018. Epub 2012 Oct 23.
404. [Modulative effect of zhenqing recipe on expressions of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in experimental type 2 diabetic rats] Zheng LY, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Jun;26 Suppl:72-6.
405. [Expression and significance of matrix metalloproteinase and tissue inhibitor of metalloproteinase in nasal cavity squamous cell carcinoma]. Zheng Y, etal., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Apr;46(4):299-302.
406. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Zhong Q and Kowluru RA, Diabetes. 2013 Jul;62(7):2559-68. doi: 10.2337/db12-1141. Epub 2013 Feb 19.
407. Inhibitory effects of alkaline extract of Citrus reticulata on pulmonary fibrosis. Zhou XM, etal., J Ethnopharmacol. 2013 Mar 7;146(1):372-8. doi: 10.1016/j.jep.2013.01.006. Epub 2013 Jan 11.
408. Favorable effects of MMP-9 knockdown in murine herpes simplex encephalitis using small interfering RNA. Zhou Y, etal., Neurol Res. 2010 Oct;32(8):801-9. doi: 10.1179/016164110X12644252260556. Epub 2010 May 18.
409. Erythromycin ameliorates cigarette-smoke-induced emphysema and inflammation in rats. Zhou Y, etal., Transl Res. 2012 Jun;159(6):464-72. doi: 10.1016/j.trsl.2011.09.007. Epub 2011 Oct 24.
Additional References at PubMed
PMID:2551898   PMID:7590350   PMID:8605986   PMID:9256427   PMID:9291580   PMID:9789069   PMID:11860503   PMID:12062105   PMID:12172377   PMID:12183632   PMID:12419962   PMID:12717622  
PMID:12832476   PMID:14523003   PMID:14575305   PMID:14643899   PMID:14663338   PMID:14707083   PMID:14732351   PMID:15051632   PMID:15111317   PMID:15146242   PMID:15211589   PMID:15240011  
PMID:15269222   PMID:15480897   PMID:15615723   PMID:15621209   PMID:15800063   PMID:15802562   PMID:15851690   PMID:15863497   PMID:15990452   PMID:16097048   PMID:16192646   PMID:16303771  
PMID:16478919   PMID:16481424   PMID:16488444   PMID:16721810   PMID:16738242   PMID:16762003   PMID:16877562   PMID:16919608   PMID:17053025   PMID:17116693   PMID:17143608   PMID:17188498  
PMID:17189680   PMID:17202418   PMID:17334234   PMID:17428795   PMID:17456343   PMID:17496904   PMID:17574586   PMID:17607299   PMID:17704059   PMID:17909100   PMID:17937912   PMID:17986262  
PMID:17987394   PMID:17996850   PMID:18000599   PMID:18031717   PMID:18052689   PMID:18073506   PMID:18077379   PMID:18247145   PMID:18264108   PMID:18292396   PMID:18320202   PMID:18352832  
PMID:18390195   PMID:18401426   PMID:18502312   PMID:18556655   PMID:18664349   PMID:18667463   PMID:18675881   PMID:18678246   PMID:18713734   PMID:18769934   PMID:18799129   PMID:18830828  
PMID:18935914   PMID:18940814   PMID:18974601   PMID:18976709   PMID:18993041   PMID:19022250   PMID:19037103   PMID:19052882   PMID:19085380   PMID:19085832   PMID:19132994   PMID:19148693  
PMID:19167969   PMID:19184368   PMID:19201691   PMID:19229995   PMID:19235898   PMID:19259351   PMID:19272421   PMID:19299917   PMID:19330523   PMID:19404732   PMID:19462901   PMID:19464272  
PMID:19478225   PMID:19497125   PMID:19524937   PMID:19537852   PMID:19551335   PMID:19570337   PMID:19607919   PMID:19685505   PMID:19703360   PMID:19734212   PMID:19838811   PMID:19847888  
PMID:19885954   PMID:19917734   PMID:20026244   PMID:20033829   PMID:20043284   PMID:20059586   PMID:20079284   PMID:20213142   PMID:20233042   PMID:20388475   PMID:20617879   PMID:20666994  
PMID:20698853   PMID:20854798   PMID:20923679   PMID:21039990   PMID:21055280   PMID:21092323   PMID:21114027   PMID:21134288   PMID:21141568   PMID:21186625   PMID:21220710   PMID:21308405  
PMID:21319376   PMID:21354273   PMID:21374976   PMID:21426744   PMID:21460212   PMID:21468558   PMID:21486558   PMID:21624254   PMID:21660948   PMID:21703213   PMID:21752621   PMID:21814480  
PMID:21884701   PMID:21896646   PMID:21941784   PMID:21952436   PMID:22071631   PMID:22092673   PMID:22098918   PMID:22105553   PMID:22135757   PMID:22182603   PMID:22191573   PMID:22207560  
PMID:22218048   PMID:22351756   PMID:22357420   PMID:22371905   PMID:22419075   PMID:22429194   PMID:22433789   PMID:22449799   PMID:22479334   PMID:22496348   PMID:22507553   PMID:22511009  
PMID:22526758   PMID:22528459   PMID:22643046   PMID:22773570   PMID:22820569   PMID:22826328   PMID:22872320   PMID:22897943   PMID:22900357   PMID:22984561   PMID:23077039   PMID:23088810  
PMID:23099153   PMID:23154389   PMID:23171679   PMID:23179310   PMID:23270462   PMID:23275087   PMID:23307413   PMID:23351884   PMID:23376485   PMID:23473787   PMID:23508111   PMID:23526543  
PMID:23533145   PMID:23585120   PMID:23601700   PMID:23619615   PMID:23646930   PMID:23708107   PMID:23800500   PMID:23819982   PMID:23845380   PMID:23867621   PMID:23886643   PMID:23891690  
PMID:23933360   PMID:23981230   PMID:23988659   PMID:24018979   PMID:24060804   PMID:24114974   PMID:24116115   PMID:24131725   PMID:24160412   PMID:24164424   PMID:24342130   PMID:24379181  
PMID:24380732   PMID:24395134   PMID:24454919   PMID:24503540   PMID:24560960   PMID:24704305   PMID:24704473   PMID:24722316   PMID:24815146   PMID:24935409   PMID:25004875   PMID:25013773  
PMID:25028660   PMID:25063292   PMID:25086360   PMID:25159478   PMID:25232752   PMID:25261791   PMID:25326689   PMID:25343559   PMID:25380300   PMID:25529509   PMID:25537973   PMID:25595645  
PMID:25627354   PMID:25645918   PMID:25652432   PMID:25867313   PMID:25897215   PMID:25947163   PMID:25960249   PMID:25961845   PMID:26232046   PMID:26258010   PMID:26264698   PMID:26318311  
PMID:26333546   PMID:26363453   PMID:26481104   PMID:26514923   PMID:26547079   PMID:26567576   PMID:26601648   PMID:26617754   PMID:26680767   PMID:26733721   PMID:26800984   PMID:26852688  
PMID:26919547   PMID:26924185   PMID:27035767   PMID:27068509   PMID:27154762   PMID:27320964   PMID:27322513   PMID:27323108   PMID:27363270   PMID:27425890   PMID:27633189   PMID:27666960  
PMID:27760767   PMID:27826738   PMID:27893855   PMID:27902934   PMID:27937032   PMID:28157489   PMID:28199982   PMID:28257481   PMID:28259914   PMID:28260878   PMID:28280358   PMID:28392358  
PMID:28488074   PMID:28501723   PMID:28506758   PMID:28645189   PMID:28805677   PMID:28912068   PMID:28912710   PMID:29210076   PMID:29262413   PMID:29277445   PMID:29604590   PMID:30410547  
PMID:30627903   PMID:30691844   PMID:30769782   PMID:31054885   PMID:31061278   PMID:31075261   PMID:31099017   PMID:31200003   PMID:31208343   PMID:31349015   PMID:31493243   PMID:31680487  
PMID:31734396   PMID:31746394   PMID:31797986   PMID:31834839   PMID:32016994   PMID:32159248   PMID:32303987   PMID:32328952   PMID:32450187   PMID:32633388   PMID:32682824   PMID:32692220  
PMID:32881898   PMID:32990013   PMID:33023122   PMID:33162790   PMID:33220187   PMID:33228717   PMID:33468174   PMID:33571214   PMID:33611790   PMID:33636289   PMID:34063987   PMID:34160889  
PMID:34610044   PMID:34630739   PMID:34919217   PMID:35196503   PMID:35216236   PMID:35306046   PMID:36193497   PMID:36281728   PMID:36322784   PMID:36438504   PMID:36925202   PMID:37356787  
PMID:37433223   PMID:37700592   PMID:37936436   PMID:38043722   PMID:38321559   PMID:38501247   PMID:38811382   PMID:39169203  


Genomics

Comparative Map Data
Mmp9
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr83174,103,474 - 174,111,434 (+)NCBIGRCr8
mRatBN7.23153,684,158 - 153,692,118 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl3153,683,858 - 153,692,120 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx3157,492,813 - 157,500,796 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.03165,991,783 - 165,999,766 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.03163,735,564 - 163,743,543 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.03161,413,410 - 161,421,473 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl3161,413,298 - 161,421,520 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.03167,578,904 - 167,605,890 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.43155,985,473 - 155,993,433 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.13155,891,508 - 155,899,467 (+)NCBI
Celera3152,289,466 - 152,297,426 (+)NCBICelera
Cytogenetic Map3q42NCBI
MMP9
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh382046,008,908 - 46,016,561 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl2046,008,908 - 46,016,561 (+)EnsemblGRCh38hg38GRCh38
GRCh372044,637,547 - 44,645,200 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 362044,070,954 - 44,078,607 (+)NCBINCBI36Build 36hg18NCBI36
Build 342044,070,953 - 44,078,606NCBI
Celera2041,348,998 - 41,356,660 (+)NCBICelera
Cytogenetic Map20q13.12NCBI
HuRef2041,378,970 - 41,386,505 (+)NCBIHuRef
CHM1_12044,540,180 - 44,547,844 (+)NCBICHM1_1
T2T-CHM13v2.02047,744,921 - 47,752,589 (+)NCBIT2T-CHM13v2.0
Mmp9
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm392164,782,246 - 164,797,770 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl2164,782,700 - 164,797,770 (+)EnsemblGRCm39 Ensembl
GRCm382164,940,326 - 164,955,850 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl2164,940,780 - 164,955,850 (+)EnsemblGRCm38mm10GRCm38
MGSCv372164,773,751 - 164,781,346 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv362164,639,456 - 164,647,051 (+)NCBIMGSCv36mm8
Celera2170,885,579 - 170,893,176 (+)NCBICelera
Cytogenetic Map2H3NCBI
cM Map285.27NCBI
Mmp9
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495544511,295,448 - 11,303,288 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495544511,295,500 - 11,303,322 (-)NCBIChiLan1.0ChiLan1.0
MMP9
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v22151,748,843 - 51,757,462 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan12051,741,951 - 51,749,613 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v02042,346,305 - 42,354,018 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.12043,432,389 - 43,440,129 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl2043,432,389 - 43,440,129 (+)Ensemblpanpan1.1panPan2
MMP9
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12433,274,260 - 33,281,116 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2433,274,268 - 33,281,293 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha2432,801,110 - 32,807,958 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.02433,984,592 - 33,991,450 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2433,984,589 - 33,991,650 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12433,242,837 - 33,249,697 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02433,358,136 - 33,364,990 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.02433,897,331 - 33,904,192 (+)NCBIUU_Cfam_GSD_1.0
Mmp9
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024408640191,584,597 - 191,592,230 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365147,037,639 - 7,045,793 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365147,038,240 - 7,045,873 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
MMP9
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1748,179,671 - 48,186,788 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11748,179,690 - 48,186,782 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21753,819,971 - 53,827,064 (+)NCBISscrofa10.2Sscrofa10.2susScr3
MMP9
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1217,867,267 - 17,874,757 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl217,867,177 - 17,874,712 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366605066,502,195 - 66,509,744 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Mmp9
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247908,583,457 - 8,591,713 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247908,584,399 - 8,591,763 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Mmp9
19 total Variants
miRNA Target Status (No longer updated)

Confirmed Target Of
miRNA GeneMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Mir125arno-miR-125a-5pMirtarbaseexternal_infoMicroarrayFunctional MTI (Weak)18258830
Mir664-2rno-miR-664-3pMirtarbaseexternal_infoMicroarrayFunctional MTI (Weak)18258830
Mir132rno-miR-132-3pMirtarbaseexternal_infoMicroarrayFunctional MTI (Weak)18258830

Predicted Target Of
Summary Value
Count of predictions:103
Count of miRNA genes:81
Interacting mature miRNAs:93
Transcripts:ENSRNOT00000023965
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
12879876Bw182Body weight QTL 1820.003body mass (VT:0001259)body weight (CMO:0000012)3145925360166177555Rat
2301411Bp320Blood pressure QTL 3200.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)3145925360166177555Rat
2312673Scl63Serum cholesterol level QTL 630.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)398535255168026850Rat
1300113Bp176Blood pressure QTL 1763.9arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)3145956084157309487Rat
12879872Cm97Cardiac mass QTL 970.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)3145925360166177555Rat
1598877Bp285Blood pressure QTL 2851.50.03arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3120538241165538241Rat
1578653Vnigr3Vascular neointimal growth QTL 33.1artery morphology trait (VT:0002191)artery neointimal hyperplastic lesion area (CMO:0001414)3130656562169034231Rat
12879873Cm96Cardiac mass QTL 960.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)3145925360166177555Rat
2302373Gluco39Glucose level QTL 395.01blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)398535386161695835Rat
12879874Cm98Cardiac mass QTL 980.005heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)3145925360166177555Rat
1298068Bp167Blood pressure QTL 1670.004arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3141074471169034231Rat
12879875Kidm64Kidney mass QTL 640.001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)3145925360166177555Rat
70216Cm14Cardiac mass QTL 142.1heart mass (VT:0007028)heart wet weight (CMO:0000069)331172320163586636Rat
2298477Eau4Experimental allergic uveoretinitis QTL 40.0011uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)3137398739169034231Rat
8552791Vie2Viral induced encephalitis QTL 24.1brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)3145956084169034231Rat
61335Bp20Blood pressure QTL 203arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3141339236155617360Rat
1581568Rf53Renal function QTL 53urine total protein amount (VT:0000032)urine protein excretion rate to body weight ratio (CMO:0001099)356395968161299569Rat
2317883Alcrsp26Alcohol response QTL 261.80.63response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)3145526770169034231Rat
1578754Stresp16Stress response QTL 1640.001blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)3112681431157681431Rat
1331726Bp208Blood pressure QTL 2083.129arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)3141339013162184794Rat
1598854Memor10Memory QTL 102exploratory behavior trait (VT:0010471)average horizontal distance between subject and target during voluntary locomotion in an experimental apparatus (CMO:0002674)3145956084161299569Rat
9589106Insul23Insulin level QTL 2313.860.001blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)3131635904169034231Rat
10755461Coatc16Coat color QTL 16coat/hair pigmentation trait (VT:0010463)pigmented ventral coat/hair area to total ventral coat/hair area ratio (CMO:0001812)3122438700167438700Rat
8662816Vetf4Vascular elastic tissue fragility QTL 44renal artery integrity trait (VT:0010642)number of ruptures of the internal elastic lamina of the renal arteries (CMO:0002563)359242096157323038Rat
1559282Emca5Estrogen-induced mammary cancer QTL 53.9mammary gland integrity trait (VT:0010552)percentage of study population developing mammary tumors during a period of time (CMO:0000948)343827364169034231Rat
2303620Vencon4Ventilatory control QTL 43.9respiration trait (VT:0001943)tidal volume (CMO:0000222)3127162703168026850Rat
631841Niddm39Non-insulin dependent diabetes mellitus QTL 393.36blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)394856903159898684Rat
1576306Schws3Schwannoma susceptibility QTL 30.001nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)3118839124163839124Rat
1300159Kidm4Kidney mass QTL 43.83kidney mass (VT:0002707)right kidney wet weight to body weight ratio (CMO:0001953)3121056165157309487Rat
2301971Cm71Cardiac mass QTL 714.63heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)341874578155617519Rat
2312659Slep7Serum leptin concentration QTL 70.001blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)398535255168026850Rat
631673Iddm13Insulin dependent diabetes mellitus QTL 131.30.663blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)3130193298161695983Rat
2301970Bw81Body weight QTL 815.19body mass (VT:0001259)body weight (CMO:0000012)341874578155617519Rat
1578666Vnigr1Vascular neointimal growth QTL 14.6artery morphology trait (VT:0002191)artery lumen area (CMO:0001409)3149040888168026850Rat
1578656Vnigr2Vascular neointimal growth QTL 24.2artery morphology trait (VT:0002191)lesioned artery residual lumen area (CMO:0001417)3130656562169034231Rat
8552952Pigfal13Plasma insulin-like growth factor 1 level QTL 13blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)3138799500169034231Rat
12879871Am7Aortic mass QTL 70.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)3145925360166177555Rat
631541Bp81Blood pressure QTL 814arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3124122556169034231Rat
2312670Bw94Body weight QTL 940.01inguinal fat pad mass (VT:0010424)inguinal fat pad weight to body weight ratio (CMO:0001253)398535255168026850Rat

Markers in Region
D3Wox36  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.23153,683,950 - 153,684,056 (+)MAPPERmRatBN7.2
Rnor_6.03161,413,203 - 161,413,308NCBIRnor6.0
Rnor_5.03167,597,610 - 167,597,715UniSTSRnor5.0
RGSC_v3.43155,985,266 - 155,985,371UniSTSRGSC3.4
Celera3152,289,259 - 152,289,364UniSTS
Cytogenetic Map3q42UniSTS
PMC162218P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.23153,691,448 - 153,692,111 (+)MAPPERmRatBN7.2
Rnor_6.03161,420,804 - 161,421,466NCBIRnor6.0
Rnor_5.03167,605,211 - 167,605,873UniSTSRnor5.0
RGSC_v3.43155,992,764 - 155,993,426UniSTSRGSC3.4
Celera3152,296,757 - 152,297,419UniSTS
Cytogenetic Map3q42UniSTS
D17Mit102  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.23153,683,940 - 153,684,099 (+)MAPPERmRatBN7.2
Rnor_6.03161,413,193 - 161,413,351NCBIRnor6.0
Rnor_5.03167,597,600 - 167,597,758UniSTSRnor5.0
RGSC_v3.43155,985,256 - 155,985,414UniSTSRGSC3.4
Celera3152,289,249 - 152,289,407UniSTS
Cytogenetic Map3q42UniSTS
D2Dcr116  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.23153,683,938 - 153,684,073 (+)MAPPERmRatBN7.2
Rnor_6.03161,413,191 - 161,413,325NCBIRnor6.0
Rnor_5.03167,597,598 - 167,597,732UniSTSRnor5.0
RGSC_v3.43155,985,254 - 155,985,388UniSTSRGSC3.4
Celera3152,289,247 - 152,289,381UniSTS
Cytogenetic Map3q42UniSTS
Mmp9  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.23153,685,293 - 153,685,355 (+)MAPPERmRatBN7.2
Rnor_6.03161,414,546 - 161,414,607NCBIRnor6.0
Rnor_5.03167,598,953 - 167,599,014UniSTSRnor5.0
RGSC_v3.43155,986,609 - 155,986,670UniSTSRGSC3.4
Celera3152,290,602 - 152,290,663UniSTS
Cytogenetic Map3q42UniSTS


Genetic Models
This gene Mmp9 is modified in the following models/strains:
SS-Mmp9em4Mcwi     SS-Mmp9em6Mcwi    


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
nervous system
renal system
reproductive system
respiratory system
9 9 39 109 91 90 59 25 59 6 205 84 89 45 59 31

Sequence


Ensembl Acc Id: ENSRNOT00000023965   ⟹   ENSRNOP00000023965
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl3153,683,858 - 153,692,120 (+)Ensembl
Rnor_6.0 Ensembl3161,413,298 - 161,421,520 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000088776   ⟹   ENSRNOP00000069060
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl3153,683,858 - 153,692,120 (+)Ensembl
Rnor_6.0 Ensembl3161,413,410 - 161,420,812 (+)Ensembl
RefSeq Acc Id: NM_031055   ⟹   NP_112317
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr83174,103,474 - 174,111,434 (+)NCBI
mRatBN7.23153,684,158 - 153,692,118 (+)NCBI
Rnor_6.03161,413,410 - 161,421,473 (+)NCBI
Rnor_5.03167,578,904 - 167,605,890 (+)NCBI
RGSC_v3.43155,985,473 - 155,993,433 (+)RGD
Celera3152,289,466 - 152,297,426 (+)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_112317 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAA90911 (Get FASTA)   NCBI Sequence Viewer  
  AAB01721 (Get FASTA)   NCBI Sequence Viewer  
  CAD27893 (Get FASTA)   NCBI Sequence Viewer  
  EDL96479 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000023965
GenBank Protein P50282 (Get FASTA)   NCBI Sequence Viewer  
  QST77665 (Get FASTA)   NCBI Sequence Viewer  
RefSeq Acc Id: NP_112317   ⟸   NM_031055
- Peptide Label: precursor
- UniProtKB: P50282 (UniProtKB/Swiss-Prot),   D3ZYK8 (UniProtKB/TrEMBL),   A6JXD0 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000023965   ⟸   ENSRNOT00000023965
Ensembl Acc Id: ENSRNOP00000069060   ⟸   ENSRNOT00000088776
Protein Domains
Fibronectin type-II

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P50282-F1-model_v2 AlphaFold P50282 1-708 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13692672
Promoter ID:EPDNEW_R3196
Type:single initiation site
Name:Mmp9_1
Description:matrix metallopeptidase 9
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.03161,413,391 - 161,413,451EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:621320 AgrOrtholog
BioCyc Gene G2FUF-46817 BioCyc
Ensembl Genes ENSRNOG00000017539 Ensembl, ENTREZGENE
Ensembl Transcript ENSRNOT00000023965 ENTREZGENE
Gene3D-CATH 2.10.10.10 UniProtKB/Swiss-Prot
  2.110.10.10 UniProtKB/Swiss-Prot
  3.40.390.10 UniProtKB/Swiss-Prot
InterPro FN_type2_dom UniProtKB/Swiss-Prot
  FN_type2_sf UniProtKB/Swiss-Prot
  Hemopexin-like_dom UniProtKB/Swiss-Prot
  Hemopexin-like_dom_sf UniProtKB/Swiss-Prot
  Hemopexin-like_repeat UniProtKB/Swiss-Prot
  Hemopexin_CS UniProtKB/Swiss-Prot
  IPR006970 UniProtKB/Swiss-Prot
  Kringle-like UniProtKB/Swiss-Prot
  M10A_MMP UniProtKB/Swiss-Prot
  MetalloPept_cat_dom_sf UniProtKB/Swiss-Prot
  Pept_M10_metallopeptidase UniProtKB/Swiss-Prot
  Pept_M10A UniProtKB/Swiss-Prot
  Pept_M10A_Zn_BS UniProtKB/Swiss-Prot
  Peptidase_Metallo UniProtKB/Swiss-Prot
  PGBD-like_sf UniProtKB/Swiss-Prot
KEGG Report rno:81687 UniProtKB/Swiss-Prot
NCBI Gene 81687 ENTREZGENE
PANTHER MATRIX METALLOPROTEINASE UniProtKB/Swiss-Prot
  PTHR10201:SF30 UniProtKB/Swiss-Prot
Pfam fn2 UniProtKB/Swiss-Prot
  Hemopexin UniProtKB/Swiss-Prot
  Peptidase_M10 UniProtKB/Swiss-Prot
  PF04886 UniProtKB/Swiss-Prot
PharmGKB MMP9 RGD
PhenoGen Mmp9 PhenoGen
PIRSF Peptidase_M10A_matrix UniProtKB/Swiss-Prot
PRINTS FNTYPEII UniProtKB/Swiss-Prot
  MATRIXIN UniProtKB/Swiss-Prot
PROSITE CYSTEINE_SWITCH UniProtKB/Swiss-Prot
  FN2_1 UniProtKB/Swiss-Prot
  FN2_2 UniProtKB/Swiss-Prot
  HEMOPEXIN UniProtKB/Swiss-Prot
  HEMOPEXIN_2 UniProtKB/Swiss-Prot
  ZINC_PROTEASE UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000017539 RatGTEx
SMART FN2 UniProtKB/Swiss-Prot
  SM00120 UniProtKB/Swiss-Prot
  ZnMc UniProtKB/Swiss-Prot
Superfamily-SCOP Metalloproteases ('zincins'), catalytic domain UniProtKB/Swiss-Prot
  SSF47090 UniProtKB/Swiss-Prot
  SSF50923 UniProtKB/Swiss-Prot
  SSF57440 UniProtKB/Swiss-Prot
UniProt A0A0G2JUD9_RAT UniProtKB/TrEMBL
  A0A8A1UC80_RAT UniProtKB/TrEMBL
  A0A8A1UDE0_RAT UniProtKB/TrEMBL
  A6JXD0 ENTREZGENE, UniProtKB/TrEMBL
  D3ZYK8 ENTREZGENE, UniProtKB/TrEMBL
  MMP9_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2005-01-20 Mmp9  matrix metallopeptidase 9    matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase)  Name updated 1299863 APPROVED
2002-08-07 Mmp9  matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase)      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_disease increased expression is observed in rheumatoid arthiritis and periodontal disease, highly expressed in patients with ulcerative colitis 628551
gene_expression expressed in the colonic wall tissue of colotic and normal rats 628551
gene_function zinc and calcium-dependent endopeptidase, secreted as a zymogens 628551
gene_process involved in tissue destruction and remodelling 628551
gene_process degrades type IV collagen and gelatine 628551
gene_regulation after exposure of cultured cardiac fibroblasts to IL-1 beta, expression was enhanced in cells of both SHR and WKY strains to equivalent levels as measured by both semiquantitative PCR and zymographic studies 1358958
gene_regulation expression induced by TNFalpha in testis 727488
gene_regulation oral administration of dextran sulphate sodium (DSS) induced upregulatin of pro-Mmp-9 activity, activity dependent on the extent of inflammed colonic tissue 628551